<SEC-DOCUMENT>0001062993-25-008357.txt : 20250502
<SEC-HEADER>0001062993-25-008357.hdr.sgml : 20250502
<ACCEPTANCE-DATETIME>20250502160604
ACCESSION NUMBER:		0001062993-25-008357
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20250502
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250502
DATE AS OF CHANGE:		20250502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Flora Growth Corp.
		CENTRAL INDEX KEY:			0001790169
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40397
		FILM NUMBER:		25908450

	BUSINESS ADDRESS:	
		STREET 1:		3230 W. COMMERCIAL BOULEVARD
		STREET 2:		SUITE 180
		CITY:			FORT LAUDERDALE
		STATE:			FL
		ZIP:			33309
		BUSINESS PHONE:		416-861-2267

	MAIL ADDRESS:	
		STREET 1:		3230 W. COMMERCIAL BOULEVARD
		STREET 2:		SUITE 180
		CITY:			FORT LAUDERDALE
		STATE:			FL
		ZIP:			33309
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:flgc="http://www.floragrowth.com/20250502" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">

<head>
    <title>Flora Growth Corp.: Form 8-K - Filed by newsfilecorp.com</title>
</head>

<body style="font-size:10pt;font-family:Times New Roman;">

    <div style="font-family: Times New Roman; font-size: 10pt; line-height: initial;">
        <hr style="width: 100%; color: #000000; height: 3px; background-color: black;"/><a id="page_1"></a>
        <div style="display: none;">
            <ix:header>
                <ix:hidden>
                    <ix:nonNumeric name="dei:AmendmentFlag" contextRef="CR20250502" id="ixv-164">false</ix:nonNumeric>
                    <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="CR20250502" id="ixv-165">2025-05-02</ix:nonNumeric>
                    <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="CR20250502" id="ixv-166">0001790169</ix:nonNumeric>
                    <ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="EntityTaxIdentificationNumber" contextRef="CR20250502">00-0000000</ix:nonNumeric>
                    <ix:nonNumeric name="dei:EntityRegistrantName" id="EntityRegistrantName" contextRef="CR20250502">Flora Growth Corp.</ix:nonNumeric>
                </ix:hidden>
                <ix:references>
                    <link:schemaRef xlink:href="flgc-20250502.xsd" xlink:type="simple"/>
                </ix:references>
                <ix:resources>
                    <xbrli:context id="CR20250502">
                        <xbrli:entity>
                            <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790169</xbrli:identifier>
                        </xbrli:entity>
                        <xbrli:period>
                            <xbrli:startDate>2025-05-02</xbrli:startDate>
                            <xbrli:endDate>2025-05-02</xbrli:endDate>
                        </xbrli:period>
                    </xbrli:context>
                </ix:resources>
            </ix:header>
        </div>
        <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><b><span style="font-size: 25pt;">UNITED STATES</span></b><br/><b><span style="font-size: 25pt;">SECURITIES AND EXCHANGE COMMISSION</span></b><br/>Washington, D.C. 20549<br/><b>___________________________</b></p>
        <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><b><span style="font-size: 25pt;">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="CR20250502" id="ixv-178">8-K</ix:nonNumeric></span></b></p>
        <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><b>CURRENT REPORT</b><br/><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p>
        <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;">Date of Report (Date of earliest event reported): <span style="text-decoration: underline; font-weight: bold;">
                <ix:nonNumeric name="dei:DocumentCreationDate" format="ixt:datemonthdayyearen" contextRef="CR20250502" id="ixv-179">May 2, 2025</ix:nonNumeric>
            </span></p>
        <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="text-decoration: underline; font-weight: bold; font-size: 25pt; -sec-ix-hidden: EntityRegistrantName;">FLORA GROWTH CORP.</span><br/>(Exact name of registrant as specified in its charter)</p>
        <table style="border-color: black; font-size: 10pt; border-collapse: collapse; width: 100%;">
            <tr style="vertical-align: top;">
                <td style="text-align: center;"><span style="text-decoration: underline; font-weight: bold;">
                        <ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" contextRef="CR20250502" id="ixv-180">Ontario</ix:nonNumeric>
                    </span></td>
                <td style="text-align: center; width: 33%;"><span style="text-decoration: underline; font-weight: bold;">
                        <ix:nonNumeric name="dei:EntityFileNumber" contextRef="CR20250502" id="ixv-181">001-40397</ix:nonNumeric>
                    </span></td>
                <td style="text-align: center; width: 33%;"><span style="text-decoration: underline; font-weight: bold; -sec-ix-hidden: EntityTaxIdentificationNumber;">Not Applicable</span></td>
            </tr>
            <tr style="vertical-align: top;">
                <td style="text-align: center;">(State or other jurisdiction</td>
                <td style="text-align: center; width: 33%;">(Commission</td>
                <td style="text-align: center; width: 33%;">(IRS Employer</td>
            </tr>
            <tr style="vertical-align: top;">
                <td style="text-align: center;">of incorporation)</td>
                <td style="text-align: center; width: 33%;">File Number)</td>
                <td style="text-align: center; width: 33%;">Identification No.)</td>
            </tr>
        </table>
        <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-weight: bold;">
                <ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="CR20250502" id="ixv-182">3230 W. Commercial Boulevard, Suite 180</ix:nonNumeric><br/>
            </span> <span style="text-decoration: underline; font-weight: bold;">
                <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="CR20250502" id="ixv-183">Fort Lauderdale</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" contextRef="CR20250502" id="ixv-184">Florida</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" contextRef="CR20250502" id="ixv-185">United States</ix:nonNumeric>
                <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="CR20250502" id="ixv-186">33309</ix:nonNumeric><br/>
            </span> (Address of principal executive offices) (ZIP Code)</p>
        <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="text-decoration: underline; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="CR20250502" id="ixv-187">954</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="CR20250502" id="ixv-188">842-4989</ix:nonNumeric></span></p>
        <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><span style="font-weight: bold; text-decoration: underline;">Not Applicable</span> <br/>(Former name or former address, if changed since last report)</p>
        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">
            <ix:nonNumeric name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" contextRef="CR20250502" id="ixv-189">&#9744;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
        </p>
        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">
            <ix:nonNumeric name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" contextRef="CR20250502" id="ixv-190">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
        </p>
        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">
            <ix:nonNumeric name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" contextRef="CR20250502" id="ixv-191">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
        </p>
        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">
            <ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" contextRef="CR20250502" id="ixv-192">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
        </p>
        <p style="margin-top: 10pt; margin-bottom: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</p>
        <table style="border-color: black; font-size: 10pt; border-collapse: collapse; width: 100%;">
            <tr style="vertical-align: top;">
                <td style="text-align: center; border-bottom: 1px solid;"><b>Title of each class</b></td>
                <td style="width: 5%;">&#160;</td>
                <td style="text-align: center; width: 30%; border-bottom: 1px solid;"><b>Trading Symbols</b></td>
                <td style="width: 5%;">&#160;</td>
                <td style="text-align: center; width: 30%; border-bottom: 1px solid;"><b>Name of each exchange on which registered</b></td>
            </tr>
            <tr style="vertical-align: top;">
                <td style="text-align: center;">
                    <ix:nonNumeric name="dei:Security12bTitle" contextRef="CR20250502" id="ixv-193">Common Shares, no par value</ix:nonNumeric>
                </td>
                <td style="width: 5%;">&#160;</td>
                <td style="text-align: center; width: 30%;">
                    <ix:nonNumeric name="dei:TradingSymbol" contextRef="CR20250502" id="ixv-194">FLGC</ix:nonNumeric>
                </td>
                <td style="width: 5%;">&#160;</td>
                <td style="text-align: center; width: 30%;">
                    <ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="CR20250502" id="ixv-195">NASDAQ</ix:nonNumeric> Capital Market
                </td>
            </tr>
        </table>
        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b -2 of this chapter).</p>
        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="CR20250502" id="ixv-196">&#9745;</ix:nonNumeric>
        </p>
        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox" contextRef="CR20250502" id="ixv-197">&#9744;</ix:nonNumeric>
        </p>
        <hr style="page-break-after: always; width: 100%; color: #000000; height: 5px; background-color: black;"/><a id="page_2"></a>
        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;"><b>Item 1.01 Entry into a Material Definitive Agreement</b></p>
        <p style="background-color: #ffffff; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;"><i>Private Placement</i></p>
        <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt; margin-bottom: 10pt;">On May 2, 2025, Flora Growth Corp., a corporation organized under the laws of the Province of Ontario ("<span style="text-decoration: underline;">Flora</span>" or the "<span style="text-decoration: underline;">Company</span>"), entered into a securities purchase agreement (the "<span style="text-decoration: underline;">Securities Purchase Agreement</span>") with certain investors (the "<span style="text-decoration: underline;">Investors</span>") in connection with the issuance and sale by the Company to the Investors via a private placement (the "Private Placement") of an aggregate of 3,133,011 common shares of the Company, no par value per share at a purchase price of US$0.30 per share (the "Common Shares") and 726,992 pre-funded warrants of the Company at a purchase price of US$0.2999 per warrant (the "Pre-funded Warrants") each to purchase one Common Share (each, a "Pre-funded Warrant Share") which shall be immediately exercisable and expire when exercised in full, at an exercise price of US$0.0001 per share. The Company has agreed to file a registration statement on Form S-3 within fifteen (15) calendar days following the closing date of the Private Placement.</p>
        <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt; margin-bottom: 10pt;">The Company will reimburse the Investors a non-accountable amount of US$15,000 for all costs and expenses of outside counsel and disbursements of Bevilacqua PLLC, counsel to one of the Investors, which shall be withheld by such Investor from its purchase price at the closing date of the Private Placement.&#160;</p>
        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">The net proceeds from the sale of the Common Shares and Pre-funded Warrants were approximately US$1,100,000 after deducting estimated expenses relating to the Private Placement. The Company intends to use US$400,000 of the net proceeds from the Private Placement to purchase Solana, US$400,000 of the net proceeds from the Private Placement to purchase Ethereum, US$100,000 of the net proceeds from the Private Placement to purchase Sui, US$100,000 of the net proceeds from the Private Placement to purchase Ripple, and the balance of the net proceeds from the Private Placement for general corporate and working capital purposes and to pay any fees and expenses in connection with the issuance of the Common Shares and the Pre-funded Warrants.</p>
        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">The Securities Purchase Agreement includes customary representations, warranties and covenants by the Company and the Investors. Additionally, the Company has agreed to provide the Investors with customary indemnification under the Securities Purchase Agreement against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the "<span style="text-decoration: underline;">Securities Act</span>").</p>
        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">The foregoing description of the Pre-funded Warrants and the Securities Purchase Agreement is only a summary and is qualified in its entirety by reference to the complete text of the form of Pre-funded Warrant and the form of Securities Purchase Agreement, copies of which are attached as Exhibit 4.1 and Exhibit 10.1 respectively, to this Report on Form 8-K and are incorporated by reference herein.</p>
        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;"><b>Item 3.02 Unregistered Sales of Equity Securities</b></p>
        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">The information under Item 1.01 of this Current Report on Form 8-K regarding the Private Placement is incorporated herein by reference. The Common Shares, Pre-funded Warrants and Pre-funded Warrant Shares have not been registered under the Securities Act and are instead being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and/or Rule 506(b) promulgated thereunder.</p>
        <p style="margin-bottom: 0pt; text-align: justify; margin-top: 10pt;"><b>Item 9.01 Financial Statements and Exhibits.</b></p>
        <p style="margin-top: 0pt; text-align: justify; margin-bottom: 10pt;">(d) Exhibits</p>
        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
            <tr>
                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;"><a href="exhibit10-1.htm">4.1</a></td>
                <td style="width: 95.2%; vertical-align: top; background-color: #eeeeee; text-align: justify;"><a href="exhibit10-1.htm">Form of Pre-funded Warrant dated as of May 2, 2025</a></td>
            </tr>
            <tr>
                <td style="margin-top: 0pt; margin-bottom: 0pt;"><a href="exhibit10-1.htm">10.1</a></td>
                <td style="width: 95.2%; vertical-align: top; text-align: justify;"><a href="exhibit10-1.htm">Form of Securities Purchase Agreement, dated as of May 2, 2025, by and between the Company and the purchasers identified therein</a></td>
            </tr>
            <tr>
                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">104</td>
                <td style="margin-top: 0pt; margin-bottom: 0pt; background-color: #eeeeee;">Cover Page Interactive Data File (formatted as inline XBRL)</td>
            </tr>
        </table>
        <br/>
        <hr style="break-after: page; text-align: center; height: 5px; color: #000000; background-color: #000000; width: 100%;"/><a id="page_3"></a>
        <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><b>SIGNATURES</b></p>
        <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
        <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
            <tr>
                <td style="vertical-align: top; width: 50%;">
                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                </td>
                <td style="vertical-align: top;" colspan="2">
                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><b>FLORA GROWTH CORP.</b></p>
                </td>
            </tr>
            <tr>
                <td style="vertical-align: top; width: 50%;">
                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                </td>
                <td style="vertical-align: top; width: 5%;">
                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                </td>
                <td style="vertical-align: top; width: 45%;">
                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                </td>
            </tr>
            <tr>
                <td style="vertical-align: top; width: 50%;">
                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">Date: May 2, 2025</p>
                </td>
                <td style="vertical-align: top; width: 5%;">
                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">By:</p>
                </td>
                <td style="vertical-align: top; border-bottom: 0.75pt solid #000000; width: 45%;">
                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;"><i>/s/ Clifford Starke</i></p>
                </td>
            </tr>
            <tr>
                <td style="vertical-align: top; width: 50%;">
                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                </td>
                <td style="vertical-align: top; width: 5%;">
                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">Name:</p>
                </td>
                <td style="vertical-align: top; width: 45%;">
                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">Clifford Starke</p>
                </td>
            </tr>
            <tr>
                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%; vertical-align: top;">&#160;</td>
                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 5%; vertical-align: top;">Title:</td>
                <td style="vertical-align: top; width: 45%;">Chief Executive Officer</td>
            </tr>
            <tr>
                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 50%; vertical-align: top;">&#160;</td>
                <td style="margin-top: 0pt; margin-bottom: 0pt; width: 5%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top; width: 45%;">
                    <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
                </td>
            </tr>
        </table>
        <hr style="height: 5px; color: #000000; background-color: #000000; width: 100%;"/>
    </div>

</body>

</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>

<head>
    <title>Flora Growth Corp.: Exhibit 10.1 - Filed by newsfilecorp.com</title>
</head>

<body style="font-size:10pt; font-family:'Times New Roman';">
    <hr width="100%" size="3" color="black" noshade="noshade"><a name="page_1"></a>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><b>SECURITIES PURCHASE AGREEMENT</b></p>
    <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;"><font style="width: 36pt; display: inline-block;">&#160;</font>This SECURITIES PURCHASE AGREEMENT (the "<u>Agreement</u>"), dated as of May 2, 2025, between Flora Growth Corp., an Ontario corporation (the "<u>Company</u>"), and each investor identified on the signature pages hereto (each, including its successors and assigns, an "<u>Investor</u>" and collectively, the "<u>Investors</u>"). Subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "<u>1933 Act</u>"), and/or Rule 506 promulgated thereunder, the Company desires to issue and sell to each Investor, and each Investor, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</p>
    <p style="text-indent: 72pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">THE PARTIES HEREBY AGREE AS FOLLOWS:</p>
    <p style="text-indent: 72pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">1.<font style="width: 29pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Purchase and Sale of the Securities</u>.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">1.1<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Sale and Issuance of the Securities</u>.</p>
    <p style="text-indent: 144pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(a)<font style="width: 22.68pt; text-indent: 0pt; display: inline-block;">&#160;</font>Prior to the Closing (as defined below), the Company shall have authorized (i) the sale and issuance to the Investors of the Company's Common Shares, no par value (the "<u>Shares</u>") and/or prefunded warrants to purchase Shares in the form of Exhibit A (the "<u>Prefunded Warrants</u>"),&#160; and (ii) the issuance of the Shares issuable upon exercise of the Prefunded Warrants (collectively, the "<u>Warrant Shares</u>"). The Shares, the Prefunded Warrants and the Warrant Shares are collectively referred to herein as the "<u>Securities</u>".</p>
    <p style="text-indent: 144pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(b)<font style="width: 22.01pt; text-indent: 0pt; display: inline-block;">&#160;</font>Subject to the terms and conditions of this Agreement, the Investors agree to purchase at the Closing, and the Company agrees to sell and issue to the Investors at the Closing the number of Shares and/or Prefunded Warrants set forth on the signature page hereto at a purchase price of US$0.30 per Share or US$0.2999 per Prefunded Warrant.&#160; Each Prefunded Warrant shall have an exercise price of US$0.0001 per Warrant Share purchasable thereunder.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">1.2<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Closing; Delivery</u>. Subject to the terms and conditions of this Agreement, the<b> </b>issuance of the Shares or Prefunded Warrants in lieu of Shares shall take place remotely via the exchange of documents and signatures on a day on which the principal trading market for the Company's common shares is open for trading (a "<u>Trading Day</u>") and on such day all conditions set forth in this Agreement have been satisfied (or waived as permitted herein) at such time as the Company and the Investors mutually agree upon, orally or in writing (which time and place are designated as the "<u>Closing</u>" and such date, the "<u>Closing Date</u>").</p>
    <p style="text-indent: 144pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(a)<font style="width: 22.68pt; text-indent: 0pt; display: inline-block;">&#160;</font>On or prior to the Closing, the Company shall deliver to each Investor the following:</p>
    <p style="text-indent: 157.5pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(i)<font style="width: 11.17pt; text-indent: 0pt; display: inline-block;">&#160;</font>this Agreement duly executed by the Company;</p>
    <p style="text-indent: 157.5pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(ii)<font style="width: 7.84pt; text-indent: 0pt; display: inline-block;">&#160;</font>a copy of the irrevocable instructions (the "<u>Transfer Agent Instructions</u>") to the transfer agent of the Company (the "<u>Transfer Agent</u>") instructing the Transfer Agent to deliver evidence of the issuance of such Investor's Shares as held in DRS book-entry form by the Transfer Agent and registered in the name of such Investor;</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_2"></a>
    <p style="text-indent: 157.5pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(iii)<font style="width: 4.51pt; text-indent: 0pt; display: inline-block;">&#160;</font>if applicable, a Prefunded Warrant registered in the name of such Investor; and</p>
    <p style="text-indent: 157.5pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(iv)<font style="width: 5.17pt; text-indent: 0pt; display: inline-block;">&#160;</font>wire instructions for a bank account designated by the Company.</p>
    <p style="text-indent: 144pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(b)<font style="width: 21.51pt; text-indent: 0pt; display: inline-block;">&#160;</font>On or prior to the Closing, each Investor shall deliver to the Company the following:</p>
    <p style="margin-left: 144pt; text-indent: 13.5pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(i)<font style="width: 10.17pt; text-indent: 0pt; display: inline-block;">&#160;</font> this Agreement duly executed by such Investor; and</p>
    <p style="margin-left: 121.5pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(ii)<font style="width: 7.34pt; text-indent: 0pt; display: inline-block;">&#160;</font>the Investor's subscription amount for the Shares and, if applicable, Prefunded Warrants by wire transfer to the bank account designated by the Company; and</p>
    <p style="margin-left: 121.5pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(iii)<font style="width: 4.51pt; text-indent: 0pt; display: inline-block;">&#160;</font>a duly executed, correct, complete and accurate IRS Form W-8 or W-9 (or any successor form), as applicable.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">1.3<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Use of Proceeds</u>.&#160; The Company covenants and agrees that it shall use the net proceeds of the sale of the Shares and Prefunded Warrants hereunder as follows:&#160; US$400,000 of the net proceeds will be used to purchase Solana; US$400,000 of the net proceeds will be used to purchase Ethereum; US$100,000 of the net proceeds will be used to purchase Sui; US$100,000 of the net proceeds will be used to purchase Ripple and the balance of the net proceeds will be used for general corporate and working capital purposes and to pay any fees and expenses in connection with the issuance of the Shares and the Prefunded Warrants.</p>
    <p style="text-indent: 72pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.<font style="width: 29pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Representations and Warranties of the Company</u>. The Company represents and warrants to each of the Investors that, except as set forth in the disclosure schedules attached to this Agreement (the "<u>Disclosure Schedules</u>"), which disclosure schedules shall be deemed a part hereof and shall qualify any representation made herein to the extent of the disclosure contained in the corresponding section of the Disclosure Schedules, as of the date hereof and as of the Closing Date:</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.1<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Organization, Good Standing and Qualification</u>.&#160; The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the Province of Ontario, Canada and has all requisite corporate power and authority to carry on its business as now conducted.&#160; The Company is duly qualified to transact business and is in good standing in each jurisdiction, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of this Agreement or the Prefunded Warrants, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and its Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company's ability to perform in any material respect on a timely basis its obligations under this Agreement or the Prefunded Warrants (any of (i), (ii) or (iii), a "<u>Material Adverse Effect</u>"). Other than the Persons set forth in Section 2.1 of the Disclosure Schedules, the Company has no Subsidiaries.&#160; "<u>Subsidiaries</u>" means any Person in which the Company, directly or indirectly, (I) owns any of the outstanding share capital or holds any equity or similar interest of such Person or (II) controls or operates all or any part of the business, operations or administration of such Person, and each of the foregoing, is individually referred to herein as a "<u>Subsidiary</u>.&#160; "<u>Person</u>" means any individual, corporation, partnership, limited liability company, trust, unincorporated organization, government or agency or political subdivision thereof or any other entity.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_3"></a>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.2<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Authorization; Enforcement; Validity</u>.&#160; The Company has the requisite power and authority to enter into and perform its obligations under this Agreement and the other Transaction Documents and to issue the Securities in accordance with the terms hereof and thereof.&#160; The execution and delivery of this Agreement and the other Transaction Documents by the Company, and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Shares and Prefunded Warrants and the reservation for issuance and issuance of the Warrant Shares issuable upon exercise of the Prefunded Warrants) have been duly authorized by the Company's board of directors or other governing body, as applicable, and (other than the notice and/or application(s) to the Principal Market (as defined below) and each applicable trading market for the issuance and sale of the Securities and the listing of the Shares and Warrant Shares for trading thereon in the time and manner required thereby, and the filing of Form D with the U.S. Securities and Exchange Commission (the "<u>Commission</u>"), if required,&#160; and such filings as are required to be made under applicable state securities laws (the "<u>Required Approvals</u>") no further consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority on the part of the Company or its Subsidiaries, their respective boards of directors or their shareholders or other governing body.&#160; This Agreement has been, and the other Transaction Documents to which it is a party will be prior to the Closing, duly executed and delivered by the Company, and each constitutes the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with its respective terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors' rights and remedies and except as rights to indemnification and to contribution may be limited by federal or state securities law.&#160; "<u>Transaction Documents</u>" means, collectively, this Agreement and the Prefunded Warrants and each of the other agreements and instruments entered into or delivered by any of the parties hereto in connection with the transactions contemplated hereby and thereby, as may be amended from time to time.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.3<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Valid Issuance of the Securities</u>.&#160; The Shares being purchased by the Investors hereunder, when issued, sold and delivered in accordance with the terms of this Agreement for the consideration expressed herein, will be duly and validly issued, fully paid and nonassessable and will be free of restrictions on transfer other than restrictions on transfer under this Agreement. The Prefunded Warrants being purchased by the Investors hereunder, when paid for and issued in accordance with this Agreement, will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally and subject to general principles of equity. The Warrant Shares have been duly and validly reserved for issuance and, upon issuance in accordance with the terms of the Prefunded Warrants, will be duly and validly issued, fully paid and nonassessable and will be free of restrictions on transfer other than restrictions on transfer under this Agreement, the Prefunded Warrants and applicable state and federal securities laws.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_4"></a>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.4<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>No Conflicts</u>.&#160; The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Shares, the Prefunded Warrants, and the Warrant Shares and the reservation for issuance of the Warrant Shares) will not (i) result in a violation of the articles of incorporation of the Company, as amended to date (the "<u>Articles of Incorporation</u>") (including, without limitation, any certificate of designation contained therein), bylaws or other organizational documents of the Company or any of its Subsidiaries, or any share capital or other securities of the Company or any of its Subsidiaries, (ii)&#160; conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) in any respect under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including, without limitation, foreign, federal and state securities laws and regulations and the rules and regulations of the Nasdaq Capital Market (the "<u>Principal Market</u>") and including all applicable foreign, federal and state laws, rules and regulations, including the laws, rules and regulations of Canada) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.5<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Offering</u>.&#160; Subject to the truth and accuracy of each Investor's representations and warranties set forth in Section 3 of this Agreement, the offer, sale and issuance of the Securities as contemplated by this Agreement are exempt from the registration requirements of applicable state and federal securities laws, and neither the Company nor any authorized agent acting on its behalf will take any action hereafter that would cause the loss of such exemption. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Principal Market or any other market or quotation system on which the Company's securities trade.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.6<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>No Integrated Offering</u>.&#160; None of the Company, its Subsidiaries or any of their Affiliates, nor any Person acting on their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration of the issuance of any of the 1933 Act, whether through integration with prior offerings or otherwise, or cause this offering of the Securities to require approval of shareholders of the Company for purposes of the 1933 Act or under any applicable shareholder approval provisions, including, without limitation, under the rules and regulations of any exchange or automated quotation system on which any of the securities of the Company are listed or designated for quotation.&#160; None of the Company, its Subsidiaries, their Affiliates nor any Person acting on their behalf will take any action or steps that would require registration of the issuance of any of the Securities under the 1933 Act (other than pursuant to the registration provisions of this Agreement) or cause the offering of any of the Securities to be integrated with other offerings of securities of the Company.&#160; "<u>Affiliate</u>" means, with respect to any specified Person, any other Person that directly or indirectly controls, is controlled by, or is under common control with such Person. For purposes of this definition, "control" means the possession, direct or indirect, of the power to direct or cause the direction of the management or policies of a Person, whether through ownership of voting securities, by contract, or otherwise.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.7<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>SEC Documents; Financial Statements</u>.&#160; Except as disclosed in the SEC Documents or would otherwise have a Material Adverse Effect, during the two (2) years prior to the date hereof, the Company has timely filed all reports, schedules, forms, proxy statements, statements and other documents required to be filed by it with the SEC pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the "<u>1934 Act</u>") (all of the foregoing filed prior to the date hereof and all exhibits and appendices included therein and financial statements, notes and schedules thereto and documents incorporated by reference therein being hereinafter referred to as the "<u>SEC Documents</u>").&#160; As of their respective dates, the SEC Documents complied in all material respects with the requirements of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.&#160; As of their respective dates, the financial statements of the Company included in the SEC Documents complied in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto as in effect as of the time of filing.&#160; Such financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles ("<u>GAAP</u>"), consistently applied, during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto, or (ii) in the case of unaudited interim statements, to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all material respects the financial position of the Company as of the dates thereof and the results of its operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments which will not be material, either individually or in the aggregate).&#160; The reserves, if any, established by the Company or the lack of reserves, if applicable, are reasonable based upon facts and circumstances known by the Company on the date hereof and there are no loss contingencies that are required to be accrued by the Statement of Financial Accounting Standard No. 5 of the Financial Accounting Standards Board which are not provided for by the Company in its financial statements or otherwise.&#160; No other information provided by or on behalf of the Company to any of the Investors which is not included in the SEC Documents (including, without limitation, information in the disclosure schedules to this Agreement) contains any untrue statement of a material fact or omits to state any material fact necessary in order to make the statements therein not misleading, in the light of the circumstance under which they are or were made.&#160; The Company is not currently contemplating to amend or restate any of the financial statements (including, without limitation, any notes or any letter of the independent accountants of the Company with respect thereto) included in the SEC Documents (the "<u>Financial Statements</u>"), nor is the Company currently aware of facts or circumstances which would require the Company to amend or restate any of the Financial Statements, in each case, in order for any of the Financials Statements to be in compliance with GAAP and the rules and regulations of the SEC.&#160; The Company has not been informed by its independent accountants that they recommend that the Company amend or restate any of the Financial Statements or that there is any need for the Company to amend or restate any of the Financial Statements.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_5"></a>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.8<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Absence of Certain Changes</u>.&#160; Except as disclosed in the SEC Documents, since the date of the Company's most recent audited financial statements contained in a Form 10-K, there has been no material adverse change and no material adverse development in the business, assets, liabilities, properties, operations (including results thereof), condition (financial or otherwise) or prospects of the Company or any of its Subsidiaries.&#160; Since the date of the Company's most recent audited financial statements contained in a Form 10-K, neither the Company nor any of its Subsidiaries has (i) declared or paid any dividends, (ii) sold any assets, individually or in the aggregate, outside of the ordinary course of business or (iii) made any capital expenditures, individually or in the aggregate, outside of the ordinary course of business.&#160; Except as disclosed in the Disclosure Schedules, neither the Company nor any of its Subsidiaries has taken any steps to seek protection pursuant to any law or statute relating to bankruptcy, insolvency, reorganization, receivership, liquidation or winding up, nor does the Company or any Subsidiary have any knowledge or reason to believe that any of their respective creditors intend to initiate involuntary bankruptcy proceedings or any actual knowledge of any fact which would reasonably lead a creditor to do so. The Company and its Subsidiaries, individually and on a consolidated basis, are not as of the date hereof, and after giving effect to the transactions contemplated hereby to occur at the Closing, will not be Insolvent (as defined below).&#160; For purposes of this Section 2.8, "<u>Insolvent</u>" means, (i) with respect to the Company and its Subsidiaries, on a consolidated basis, (A) the present fair saleable value of the Company's and its Subsidiaries' assets is less than the amount required to pay the Company's and its Subsidiaries' total Indebtedness (as defined below), (B) the Company and its Subsidiaries are unable to pay their debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured or (C) the Company and its Subsidiaries intend to incur or believe that they will incur debts that would be beyond their ability to pay as such debts mature; and (ii) with respect to the Company and each Subsidiary, individually, (A) the present fair saleable value of the Company's or such Subsidiary's (as the case may be) assets is less than the amount required to pay its respective total Indebtedness, (B) the Company or such Subsidiary (as the case may be) is unable to pay its respective debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured or (C) the Company or such Subsidiary (as the case may be) intends to incur or believes that it will incur debts that would be beyond its respective ability to pay as such debts mature.&#160; Neither the Company nor any of its Subsidiaries has engaged in any business or in any transaction, and is not about to engage in any business or in any transaction, for which the Company's or such Subsidiary's remaining assets constitute unreasonably small capital with which to conduct the business in which it is engaged as such business is now conducted and is proposed to be conducted. "<u>Indebtedness</u>" means, with respect to any Person, (i) all obligations for borrowed money, (ii) all obligations evidenced by bonds, debentures, notes or similar instruments, (iii) all capital lease obligations, (iv) all obligations for the deferred purchase price of property or services.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_6"></a>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.9<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>No Undisclosed Events, Liabilities, Developments or Circumstances</u>.&#160; No event, liability, development or circumstance has occurred or exists, or is reasonably expected to exist or occur with respect to the Company, any of its Subsidiaries or any of their respective businesses, properties, liabilities, prospects, operations (including results thereof) or condition (financial or otherwise), that (i) would be required to be disclosed by the Company under applicable securities laws on a registration statement on Form S-1 filed with the Commission relating to an issuance and sale by the Company of its Common Shares and which has not been publicly announced, (ii) could have a material adverse effect on any Investor's investment hereunder or (iii) could have a Material Adverse Effect.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.10<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Capitalization</u>.&#160; The authorized capital stock of the Company consists of (i) an unlimited number of Common Shares, of which, 19,435,642. are issued and outstanding.&#160; Except as disclosed in the SEC Documents, the Company has not issued any capital stock since its most recently filed periodic report under the 1934 Act.&#160; No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents.&#160; There are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any Common Shares, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional Common Shares or other securities.&#160; The issuance and sale of the Securities will not obligate the Company to issue Common Shares or other securities to any Person (other than the Investors) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any mandatory redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or "phantom stock" plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all foreign, federal and state securities laws.&#160;</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_7"></a>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.11<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Litigation</u>.&#160; Except as disclosed in the SEC Documents, there is no action, suit, proceeding or investigation pending or, to the Company's knowledge, currently threatened against the Company or the Subsidiary that questions the validity of this Agreement or the Prefunded Warrants, or the right of the Company to enter into such agreements, or to consummate the transactions contemplated thereunder, or that might result, either individually or in the aggregate, in any material adverse changes in the assets, condition or affairs of the Company or the Subsidiary, financially or otherwise, or any change in the current equity ownership of the Company or the Subsidiary, nor is the Company or the Subsidiary aware that there is any basis for the foregoing. The foregoing includes, without limitation, actions, suits, proceedings or investigations pending or threatened (or any basis therefor known to the Company) involving the prior employment of any of the Company's or the Subsidiary's employees, their use in connection with the Company's or the Subsidiary's business of any information or techniques allegedly proprietary to any of their former employers or their obligations under any agreements with prior employers.&#160; Neither the Company nor the Subsidiary is a party or subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality. There is no action, suit, proceeding or investigation by the Company or the Subsidiary currently pending or that the Company intends to initiate.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.12<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Transactions With Affiliates and Employees</u>.&#160; Except as set forth in the SEC Documents and as set forth in Section 2.12 of the Disclosure Schedule, none of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of US$120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_8"></a>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.13<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Sarbanes-Oxley; Internal Accounting Controls</u>.&#160; The Company and the Subsidiaries are in material compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the 1934 Act) that is effective to provide reasonable assurance that: (i) transactions are executed in accordance with management's general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP or any other criteria applicable to such statements, and to maintain accountability for assets, (iii) access to assets is permitted only in accordance with management's general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established and maintained disclosure controls and procedures (as defined in 1934 Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the 1934 Act is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms.&#160; The Company's certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic annual report under the 1934 Act (such date, the "<u>Evaluation Date</u>").&#160; The Company presented in its most recently filed periodic annual report under the 1934 Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date.&#160; Since the Evaluation Date, except as set forth in Section 2.13 of the Disclosure Schedule, there have been no changes in the internal control over financial reporting (as such term is defined in the 1934 Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.14<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Investment Company</u>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate of, an "investment company" within the meaning of the Investment Company Act of 1940, as amended.&#160; The Company shall conduct its business in a manner so that it will not become an "investment company" subject to registration under the Investment Company Act of 1940, as amended.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.15<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Listing and Maintenance Requirements</u>.&#160; The Common Shares are registered pursuant to Section 12(b) of the 1934 Act, and, except as set forth in Section 2.15 of the Disclosure Schedules, the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Shares under the 1934 Act nor has the Company received any notification that the Commission is contemplating terminating such registration.&#160; Except as set forth in the SEC Documents or Section 2.15 of the Disclosure Schedules, the Company has not in the 12 months preceding the date hereof received notice from the Principal Market or any other trading Market on which Common Shares are or have been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Principal Market or other trading market. Except as set forth in the SEC Documents or Section 2.15 of the Disclosure Schedules, the Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Shares are currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_9"></a>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.16<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Application of Takeover Protections</u>.&#160; No control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti takeover provision under the Company's Articles of Incorporation (or similar charter documents) or the laws of Ontario, Canada that is or could become applicable to the Investors as a result of the Investors and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company's issuance of the Securities and the Investors' ownership of the Securities, is applicable to the Company.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.17<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Tax Status</u>.&#160; Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply.&#160; There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.18<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>No General Solicitation</u>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Securities by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to the Investors and certain other "accredited investors" within the meaning of Rule 501 under the 1933 Act</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.19<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Foreign Corrupt Practices</u>.&#160; Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other Person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any Person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.20<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>No Disagreements with Accountants and Lawyers</u>.&#160; There are no disagreements of any kind presently existing, or reasonably anticipated by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company and the Company is current with respect to any fees owed to its accountants and lawyers which could affect the Company's ability to perform any of its obligations under any of the Transaction Documents.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_10"></a>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.21<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Acknowledgment Regarding Investors' Purchase of Securities</u>.&#160; The Company acknowledges and agrees that the Investors are acting solely in the capacity of an arm's length Investor with respect to the Transaction Documents and the transactions contemplated thereby.&#160; The Company further acknowledges that no Investor is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Investor or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Investors' purchase of the Securities.&#160; The Company further represents to the Investors that the Company's decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.22<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Regulation M Compliance</u>.&#160; The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.23<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Office of Foreign Assets Control</u>.&#160; Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent, employee or Affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.24<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Money Laundering</u>.&#160; The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable U.S. and foreign financial record-keeping and reporting requirements, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the "<u>Money Laundering Laws</u>"), and no Action (as defined below), suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.25<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>No Disqualification Events</u>. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506 under the 1933 Act, none of the Company, any of its predecessors, any Affiliated issuer, any director, executive officer, other officer of the Company participating in the offering hereunder, any beneficial owner of twenty percent (20%) or more of the Company's outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the 1933 Act) connected with the Company in any capacity at the time of sale (each, an "<u>Issuer Covered Person</u>" and, together, "<u>Issuer Covered Persons</u>") is subject to any of the "Bad Actor" disqualifications described in Rule 506(d)(1)(i) to (viii) under the 1933 Act (a "<u>Disqualification Event</u>"), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Investors a copy of any disclosures provided thereunder.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_11"></a>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.26<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Disclosure</u>.&#160; All of the disclosure furnished by or on behalf of the Company to the Investors regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The Company acknowledges and agrees that no Investor makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3 hereof.</p>
    <p style="text-indent: 72pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">3.<font style="width: 29pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Representations and Warranties of the Investor</u>s.&#160; Each Investor hereby represents and warrants to the Company on the date hereof and on the Closing Date that:</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">3.1<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Authorization</u>.&#160; Such Investor is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder and thereunder. Such Investor has full power and authority to enter into this Agreement, and the Agreement constitutes its valid and legally binding obligation, enforceable against such Investor in accordance with its terms except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors' rights generally, and (b) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies.&#160; The execution, delivery and performance of this Agreement by such Investor and the consummation by it of the transactions contemplated thereby have been duly and validly authorized by all necessary all necessary corporate, partnership, limited liability company or similar legal action, as applicable, and no further consent or authorization of such Investor is required.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">3.2<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>No Conflict</u>.&#160; The execution, delivery and performance of this Agreement by such Investor and the consummation by such Investor of the transactions contemplated thereby will not (a) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, any material agreement to which such Investor is a party or by which such Investor is bound or to which any of the property or assets of such Investor is subject, (b) conflict with or result in any violation of the provisions of the organizational documents of such Investor, or (c) violate any statute, order, rule or regulation of any court or governmental agency or body having jurisdiction over such Investor or the property or assets of such Investor, except in the case of clauses (a) and (c), for such conflicts, breaches, violations or defaults as would not prevent the consummation of the transactions contemplated by this Agreement.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">3.3<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Purchase Entirely for Own Account</u>.&#160; This Agreement is made with such Investor in reliance upon such Investor's representation to the Company, which by such Investor's execution of this Agreement such Investor hereby confirms, that the Securities will be acquired for investment for such Investor's own account, not as a nominee or agent, and not with a view to the distribution of any part thereof in violation of the 1933 Act or any applicable federal or state securities laws, and that such Investor has no present intention of selling, granting any participation in or otherwise distributing the same. By executing this Agreement, such Investor further represents that such Investor does not have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant participations to such Person or to any third Person, with respect to any of the Securities. Such Investor is acquiring the Securities hereunder in the ordinary course of its business.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_12"></a>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">3.4<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Disclosure of Information</u>.&#160; Such Investor believes it has received all the information it considers necessary or appropriate for deciding whether to purchase the Securities. Such Investor further represents that it has had an opportunity to ask questions and received answers from the Company regarding the terms and conditions of the offering of the Securities, the merits and risks of investing in the Securities and the business, properties, prospects and financial condition of the Company. Such Investor has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to its acquisition of the Securities.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">3.5<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Experience</u>.&#160; Such Investor, either alone or together with its representatives, is an investor in securities of companies in the development stage and acknowledges that it is able to fend for itself, can bear the economic risk of its investment, and has such knowledge, sophistication and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the Securities and has so evaluated the merits and risks of such investment.&#160; If other than an individual, Investor also represents it has not been organized for the purpose of acquiring the Securities.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">3.6<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Investor Status</u>.&#160; At the time such Investor was offered the Securities, it was, and as of the date hereof it is, and on each date on which it exercises any Prefunded Warrants, it will be either (i) an "accredited investor" within the meaning of Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Act or (ii) a "qualified institutional buyer" as defined in Rule 144A(a) under the 1933 Act.&#160;</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">3.7<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>No Disqualification Events</u>.&#160; Neither (A) the Investor, (B) any of its directors, managers, executive officers, other officers that may serve as a director, manager or officer of any company in which it invests, general partners or managing members, nor (C) any beneficial owner of the Company's voting equity securities (in accordance with Rule 506(d) of the Act) held by the Investor is subject to any "bad actor" disqualifications described in Rule 506(d)(1)(i) through (viii) under the Act.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">3.8<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Restricted Securities</u>.&#160; Such Investor understands that the Securities will be characterized as "restricted securities" under the federal securities laws inasmuch as the Securities have been registered under the Act or under the "blue sky" laws of any jurisdiction and that under such laws and applicable regulations such securities may be resold only if registered pursuant to the Act or without registration under the Act, if eligible, pursuant to the provisions of Rule 144 promulgated by the Commission pursuant to the Act ("<u>Rule 144</u>") or pursuant to another available exemption from the registration requirement of the Act.&#160; Such Investor represents that it is familiar with Rule 144, and understands the resale limitations imposed thereby and by the Act.&#160; Such Investor has been advised and understands that the Company, in issuing the Securities, is relying upon, among other things, the representations and warranties of such Investor contained in this Section 3 in concluding that such issuance is a "private offering" and is exempt from the registration provisions of the Act. Such Investor is aware that the Company is under no obligation to effect any such registration with respect to the Securities, or to file for or comply with any exemption from registration, except as otherwise contemplated in this Agreement.&#160;</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_13"></a>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">3.9<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Exculpation Among Investors</u>.&#160; The Investor acknowledges that it is not relying upon any Person, firm or corporation in making its investment or decision to invest in the Company.&#160; Neither the Investor nor any of its controlling persons, officers, directors, partners, agents or employees shall be liable to any other equity holder in the Company for any action heretofore or hereafter taken or omitted to be taken by any of them in connection with the purchase of the Securities.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">3.10<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Foreign Investors</u>.&#160; If the Investor is not a United States person (as defined by Section 7701(a)(30) of the Internal Revenue Code), the Investor hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Securities or any use of this Agreement, including (i) the legal requirements within its jurisdiction for the purchase of the Securities, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or transfer of the Securities. The Investor's subscription and payment for and continued beneficial ownership of the Securities will not violate any applicable securities or other laws of the Investor's jurisdiction.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">3.11<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>No General Solicitation</u>.&#160; Such Investor is not, to such Investor's knowledge, purchasing the Securities as a result of any advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or, to the knowledge of such Investor, any other general solicitation or general advertisement.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">3.12<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Residence</u>.&#160; If the Investor is an individual, then the Investor resides in the state or province identified in the address of the Investor set forth on the signature page hereto; if the Investor is a partnership, corporation, limited liability company or other entity, then the office or offices of the Investor in which its principal place of business is identified in the address or addresses of the Investor set forth on the signature page hereto.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">3.13<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Certain Fees</u>. No fees or commissions are or will be payable by such Investor to brokers, finders or investment bankers with respect to the purchase of any of the Securities or the consummation of the transactions contemplated by this Agreement. The Investor agrees that it will indemnify and hold harmless the Company from and against any and all claims, demands or liabilities for broker's, finder's, placement, or other similar fees or commissions incurred by such Investor or alleged to have been incurred by such Investor in connection with the purchase of the Securities or the consummation of the transactions contemplated by this Agreement.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_14"></a>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">3.14<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Information</u>. Such Investor shall cooperate reasonably with the Company to provide any information necessary for the Company to make any applicable filings, including but not limited to, filings with the Commission and pursuant to applicable state securities laws.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">3.15<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Reliance by the Company</u>. Such Investor understands that the Securities are being offered and sold in reliance on a transactional exemption from the registration requirements of federal and state securities laws and that the Company is relying upon the truth and accuracy of the representations, warranties, agreements, acknowledgments and understandings of such Investor set forth herein in order to determine the applicability of such exemptions and the suitability of such Investor to acquire the Securities.</p>
    <p style="text-indent: 72pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">4.<font style="width: 29pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Other Agreements.</u></p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">4.1<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Transfer Restrictions</u>.</p>
    <p style="text-indent: 144pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(a)<font style="width: 22.68pt; text-indent: 0pt; display: inline-block;">&#160;</font>The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Securities other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of an Investor or in connection with a pledge as contemplated in Section 4.1(c), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Securities under the 1933 Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and shall have the rights and obligations of an Investor under this Agreement.</p>
    <p style="text-indent: 144pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(b)<font style="width: 22.01pt; text-indent: 0pt; display: inline-block;">&#160;</font>The Investors agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Securities that are certificated in substantially the following form:</p>
    <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">[NEITHER] THIS SECURITY [NOR THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS SECURITY IS] HAS [NOT] BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE AND THIS SECURITY WAS ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") AND SIMILAR EXEMPTIONS UNDER APPLICABLE STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY [AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY] MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN "ACCREDITED INVESTOR" AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_15"></a>
    <p style="text-indent: 144pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(c)<font style="width: 22.68pt; text-indent: 0pt; display: inline-block;">&#160;</font>The Company acknowledges and agrees that an Investor may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an "accredited investor" as defined in Rule 501(a) under the 1933 Act and, if required under the terms of such arrangement, such Investor may transfer pledged or secured Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate Investor's expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities, the preparation and filing of any required prospectus supplement under Rule 424(b)(3) under the 1933 Act.</p>
    <p style="text-indent: 144pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(d)<font style="width: 22.01pt; text-indent: 0pt; display: inline-block;">&#160;</font>Certificates evidencing the Shares and the Warrant Shares shall not contain any legend (including the legend set forth in Section 4.1(b)) (i) while a registration statement covering the resale of such security is effective under the 1933 Act, (ii) following any sale of such Shares or Warrant Shares pursuant to Rule 144, (iii) if such Shares or Warrant Shares are eligible for sale under Rule 144 without the requirement for the Company to be in compliance with the current public information requirements under Rule 144 and without volume or manner-of-sale restrictions, or (iv) if such legend is not required under applicable requirements of the 1933 Act (including judicial interpretations and pronouncements issued by the staff of the Commission) (the date on which any of the foregoing conditions are satisfied with respect to particular Shares or Warrant Shares, the "<u>Legend Removal Date</u>"). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent or to the Investor promptly after the Legend Removal Date if required by the Transfer Agent to effect the removal of the legend or if requested by an Investor. Following the Legend Removal Date, or at such time as such legend is no longer required under this Section 4.1(d), the Company shall, no later than two (2) Trading Days after delivery by an Investor to the Company or the Transfer Agent of a certificate representing the Shares or the Warrant Shares issued with a restrictive legend, deliver or cause to be delivered to such Investor a certificate representing such Shares or Warrant Shares that is free from all restrictive and other legends. The Company shall not make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section 4.1(d), and certificates for Shares and Warrant Shares subject to legend removal hereunder shall be transmitted by the Transfer Agent to the Investor by crediting the account of the Investor's prime broker with the Depository Trust Company system as directed by such Investor.</p>
    <p style="text-indent: 144pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(e)<font style="width: 22.68pt; text-indent: 0pt; display: inline-block;">&#160;</font>In addition to such Investor's other available remedies, the Company shall pay to an Investor, in cash, (i) as partial liquidated damages and not as a penalty, for each US$1,000 of Shares or Warrant Shares delivered for removal of the restrictive legend and subject to Section 4.1(d), US$5 per Trading Day (increasing to US$10 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day after the Legend Removal Date until such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to an Investor by the Legend Removal Date a certificate representing the Shares or Warrant Shares so delivered to the Company by such Investor that is free from all restrictive and other legends and (b) if after the Legend Removal Date such Investor purchases (in an open market transaction or otherwise) Common Shares to deliver in satisfaction of a sale by such Investor of all or any portion of the number of Shares or Warrant Shares, or a sale of a number of Common Shares equal to all or any portion of the number of Shares or Warrant Shares that such Investor anticipated receiving from the Company without any restrictive legend, then, an amount equal to the excess of such Investor's total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the Common Shares so purchased (the "<u>Buy-In Price</u>") over the product of (A) such number of Shares or Warrant Shares that the Company was required to deliver to such Investor by the Legend Removal Date multiplied by (B) the lowest closing sale price of the Common Shares on any Trading Day during the period commencing on the date of delivery by such Investor to the Company of the applicable Shares or Warrant Shares and ending on the date of such delivery and payment under this clause (ii).</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_16"></a>
    <p style="text-indent: 144pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(f)<font style="width: 24.01pt; text-indent: 0pt; display: inline-block;">&#160;</font>Each Investor, severally and not jointly with the other Investors, agrees with the Company that such Investor will sell any Securities pursuant to either the registration requirements of the 1933 Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if Securities are sold pursuant to a registration statement, they will be sold in compliance with the plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend from certificates representing Securities as set forth in this Section 4.1 is predicated upon the Company's reliance upon this understanding.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">4.2<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Furnishing of Information</u>.&#160; While any Investor holds Securities, the Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the 1934 Act.&#160;</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">4.3<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Integration</u>.&#160; The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the 1933 Act) that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">4.4<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Securities Laws Disclosure; Publicity</u>.&#160; The Company shall promptly file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the Commission.&#160; From and after the issuance of the Form 8-K, the Company represents to the Investors that it shall have publicly disclosed all material, non-public information delivered to any of the Investors by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection with the transactions contemplated by the Transaction Documents.&#160;</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">4.5<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Indemnification of Investors</u>.&#160; Subject to the provisions of this Section 4.5, the Company will indemnify and hold the Investors and their directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls the Investor (within the meaning of Section 15 of the 1933 Act and Section 20 of the 1934 Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a "<u>Investor Party</u>") harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys' fees and costs of investigation that any the Investor Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any Action instituted against the Investor Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of the Investor Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such Action is solely based upon a material breach of the Investor Party's representations, warranties or covenants under the Transaction Documents or any agreements or understandings the Investor Party may have with any such stockholder or any violations by the Investor Party of state or federal securities laws or any conduct by the Investor Party which constitutes fraud, gross negligence or willful misconduct).&#160; If any Action shall be brought against any Investor Party in respect of which indemnity may be sought pursuant to this Agreement, the Investor Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Investor Party.&#160; Any Investor Party shall have the right to employ separate counsel in any such Action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of the Investor Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such Action there is, in the reasonable opinion of Investors' counsel, a material conflict on any material issue between the position of the Company and the position of the Investor Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel.&#160; The Company will not be liable to any Investor Party under this Agreement (y) for any settlement by an Investor Party effected without the Company's prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Investor Party's breach of any of the representations, warranties, covenants or agreements made by the Investor Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.5 shall be made by advancement of periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Investor Party against the Company or others and any liabilities the Company may be subject to pursuant to law; provided, however, that no Investor shall be entitled to any double recovery of damages as a result of the exercise of any other such right.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_17"></a>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">4.6<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Listing of Common Shares</u>.&#160; The Company hereby agrees to take all action immediately prior to the date hereof to file a Listing of Additional Shares Notification Form with the Principal Market relating to the transaction contemplated hereby.&#160; The Company will use commercially reasonable efforts to maintain the listing or quotation of the Common Shares on the Principal Market on which it is currently listed. The Company further agrees, if the Company applies to have the Common Shares traded on any other trading market, it will then include in such application all of the Shares and the Warrant Shares and will take such other action as is necessary to cause all of the Shares and the Warrant Shares to be listed or quoted on such other trading market as promptly as possible.&#160; The Company will then take all action reasonably necessary to continue the listing and trading of its Common Shares on a Trading Market and will comply in all respects with the Company's reporting, filing and other obligations under the bylaws or rules of the Principal Market and any other trading market.&#160; The Company agrees to maintain the eligibility of the Common Shares for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_18"></a>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">4.7<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Available Common Shares</u>. As of the date of this Agreement, the Company has capacity under the rules and regulations of the Principal Market to issue up to 3,885,184.&#160; Common Shares without obtaining Shareholder Approval.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">4.8<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Resale Registration.</u></p>
    <p style="text-indent: 144pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(a)<font style="width: 22.68pt; text-indent: 0pt; display: inline-block;">&#160;</font>The Company shall prepare and file with the Commission a resale registration statement on Form S-3 (or, if Form S-3 is not then available to the Company, such other form as is then available to register the resale of the Shares and Warrant Shares) covering the resale of all of the Shares and Warrant Shares issued pursuant to this Agreement (the "<u>Registration Statement</u>") no later than fifteen (15) calendar days following the Closing Date (the "<u>Filing Date</u>"). The Company shall use commercially reasonable to cause the Registration Statement to be declared effective by the Commission as promptly as practicable, but in any event no later than sixty (60) calendar days following the Closing Date (the "<u>Effectiveness Date</u>"). If the Commission notifies the Company that it will not review the Registration Statement or has no comments thereto, the Company shall cause the Registration Statement to be declared effective no later than five (5) Trading Days after the date on which the Company receives such notification from the Commission. The Company shall also take all actions necessary to maintain the continuous effectiveness of the Registration Statement for so long as any Shares or Warrant Shares remain outstanding and are not freely tradable without restriction under Rule 144. The Company shall qualify or register such securities under applicable blue sky laws in such jurisdictions as reasonably requested by the Investors; provided, however, that the Company shall not be required to qualify to do business, subject itself to general service of process, or become subject to taxation in any such jurisdiction. The Company shall bear all expenses related to the filing, registration, and effectiveness of the Registration Statement, other than underwriting discounts and commissions applicable to the resale of such securities by the Investors.</p>
    <p style="text-indent: 144pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(b)<font style="width: 22.01pt; text-indent: 0pt; display: inline-block;">&#160;</font>If (i) the Registration Statement is not filed with the Commission on or before the Filing Date, (ii) the Registration Statement has not been declared effective by the Commission on or before the Effectiveness Date, except to the extent such failure to cause the Registration Statement to be declared effective is due solely to a delay in the Commission's review process, provided that the Company has (A) promptly and fully responded to all comments received from the Commission (and in any event as promptly as reasonably practicable, but no later than five (5) Business Days after receipt of such comments unless responding within such period is not reasonably practicable, in which case the Company shall respond as soon as reasonably practicable thereafter) and (B) otherwise used its commercially reasonable efforts to resolve any comments as promptly as practicable, or (iii) after the Registration Statement has been declared effective, it ceases to remain continuously effective, or the Investors are otherwise unable to use the prospectus included therein to resell the Shares and Warrant Shares for any period of more than fifteen (15) consecutive calendar days or more than an aggregate of thirty (30) calendar days (whether or not consecutive) during any twelve (12)-month period (each, an "<u>Event</u>," and the date on which such Event occurs, the "<u>Event Date</u>"), then, in addition to any other rights available to the Investors, the Company shall pay to each Investor, as partial liquidated damages and not as a penalty, an amount in cash equal to one-and-a-half (1.5%) of the Subscription Amount paid by such Investor for each thirty (30)-day period (pro-rated for partial periods) that any such Event remains uncured. Liquidated damages shall accrue and be payable on a daily basis, without the need for any demand or notice by the Investors. If the Company fails to make any payment pursuant to this Section 4.8(b) when due, the Company shall pay interest on such overdue amounts at a rate of eighteen percent (18%) per annum (or, if lower, the maximum amount permitted by applicable law), accruing daily from the date due until paid in full. The obligations set forth in this Section 4.8 shall survive any termination of this Agreement and shall be in addition to any other rights or remedies available to the Investors at law or in equity.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_19"></a>
    <p style="text-indent: 144pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(c)<font style="width: 22.68pt; text-indent: 0pt; display: inline-block;">&#160;</font>The Company shall indemnify, defend and hold harmless each Investor, its affiliates, and their respective directors, officers, partners, members, managers, employees, agents and representatives, and each underwriter, if any, and each person, if any, who controls any Investor or underwriter within the meaning of the 1933 Act or the 1934 Act, against any and all losses, claims, damages, liabilities and expenses (including reasonable attorneys' fees and expenses) arising out of or based upon (i) any untrue statement or alleged untrue statement of a material fact contained in any Registration Statement, any prospectus or any amendment or supplement thereto, or (ii) any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as the same arise out of or are based upon information furnished in writing to the Company by such Investor or underwriter expressly for use therein. The Company shall also reimburse such persons for any legal or other expenses reasonably incurred in connection with investigating, defending or settling any such loss, claim, damage, liability or action. In the event that the foregoing indemnification is unavailable or insufficient to hold any such person harmless, then the Company shall contribute to the amount paid or payable by such person as a result of such losses, claims, damages, liabilities or expenses in such proportion as is appropriate to reflect the relative fault of the Company, on the one hand, and the Investor, underwriter or controlling person, on the other hand, in connection with the statements or omissions that resulted in such loss, claim, damage, liability or expense. The obligations of the Company under this Section 4.8(c) shall survive the completion of the offering and any termination of this Agreement.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">4.9<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Certain Transactions and Confidentiality</u>. Each of the Investors covenants that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including short sales of any of the Company's securities during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the Form 8-K as described in Section 4.4.&#160; Each of the Investors covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the Form 8-K as described in Section 4.4, the Investor will maintain the confidentiality of the existence and terms of this transaction and the information included herein.&#160; Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) none of the Investors makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the Form 8-K as described in Section 4.4, (ii) no Investor shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the Form 8-K as described in Section 4.4 and (iii) no Investor shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company or its Subsidiaries after the issuance of the Form 8-K as described in Section 4.4.&#160; Notwithstanding the foregoing, in the case of an Investor that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of the Investor's assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of the Investor's assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_20"></a>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">4.10<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Blue Sky Filings</u>. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Investors at the Closing under applicable securities or "Blue Sky" laws of the states of the United States, and shall provide evidence of such actions promptly upon request of any Investor.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">4.11<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Pledge of Securities</u>. Notwithstanding anything to the contrary contained in this Agreement, the Company acknowledges and agrees that the Securities may be pledged by the Investors in connection with a bona fide margin agreement or other loan or financing arrangement that is secured by the Securities. The pledge of Securities shall not be deemed to be a transfer, sale or assignment of the Securities hereunder, and Investor effecting a pledge of Securities shall not be required to provide the Company with any notice thereof or otherwise make any delivery to the Company pursuant to this Agreement or any other Transaction Document. The Company hereby agrees to execute and deliver such documentation as a pledgee of the Securities may reasonably request in connection with a pledge of the Securities to such pledgee by an Investor.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">4.12<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Reservation of Common Shares</u>. So long as any of the Prefunded Warrants remain outstanding, the Company shall take all action necessary to at all times have authorized, and reserved for the purpose of issuance, no less than 100% of the maximum number of Common Shares issuable upon exercise of all the Prefunded Warrants (without regard to any limitations on the exercise of the Preferred Shares set forth therein).</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">4.13<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Restructure of Terms</u>. In the event any changes in the terms of this Agreement or the Securities are required by a Trading Market, the Investors, in their sole discretion, may opt to terminate this Agreement or proceed with such terms as necessary to obtain all required approvals.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_21"></a>
    <p style="text-indent: 72pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">5.<font style="width: 29pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Miscellaneous</u>.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">5.1<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Governing Law; Specific Enforcement; Submission to Jurisdiction; Waiver of Jury Trial.</u> This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed entirely within such state, without regard to the conflicts of law principles of such state.</p>
    <p style="text-indent: 144pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(b)<font style="width: 22.01pt; text-indent: 0pt; display: inline-block;">&#160;</font>The parties hereto acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached.&#160; It is accordingly agreed that the parties hereto shall be entitled to an injunction or injunctions, specific performance or other equitable relief to prevent breaches or threatened breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in the courts described in this Section 5.1, without proof of damages or otherwise (in each case, subject to the terms and conditions of this Section 5.1) (and each party hereto acknowledges and agrees that any party seeking an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in accordance with this Section 5.1 shall not be required to provide any bond or other security in connection with any such order or injunction), this being in addition to any other remedy to which they are entitled at law or in equity.&#160; The parties hereto agree not to assert that a remedy of specific enforcement is unenforceable, invalid, contrary to Law or inequitable for any reason, or that a remedy of monetary damages would provide an adequate remedy or that the parties otherwise have an adequate remedy at law.</p>
    <p style="text-indent: 144pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(c)<font style="width: 22.68pt; text-indent: 0pt; display: inline-block;">&#160;</font>Each of the parties hereto irrevocably and unconditionally submits to the exclusive jurisdiction of the Supreme Court of the State of New York, New York County, and the United States District Court for the Southern District of New York, for the purposes of any demand, action, suit, countersuit, arbitration, inquiry, proceeding or investigation by or before any governmental entity or any arbitration or mediation tribunal ("<u>Action</u>") or other proceeding arising out of this Agreement and the rights and obligations arising hereunder, and irrevocably and unconditionally waives any objection to the laying of venue of any such Action or proceeding in any such court, and further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such Action or proceeding has been brought in an inconvenient forum.&#160; Each party hereto agrees that service of any process, summons, notice or document by registered mail to such party's respective address set forth on the signature pages attached hereto shall be effective service of process for any such Action or proceeding.</p>
    <p style="text-indent: 144pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(d)<font style="width: 22.01pt; text-indent: 0pt; display: inline-block;">&#160;</font>EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION, CLAIM OR OTHER PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT. EACH PARTY HERETO (i) CERTIFIES THAT NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY ACTION, CLAIM OR OTHER PROCEEDING, SEEK TO ENFORCE THE FOREGOING WAIVER, (ii) IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVER, (iii) IT MAKES SUCH WAIVER VOLUNTARILY AND (iv) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 5.1.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_22"></a>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">5.2<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Counterparts</u>.&#160; This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one (1) and the same instrument. In the event that any signature is delivered by e-mail delivery of a ".pdf" format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such ".pdf" signature page were an original thereof.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">5.3<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Titles and Subtitles</u>.&#160; The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">5.4<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Notices</u>.&#160; All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by e-mail or facsimile, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.&#160; All communications shall be sent to the respective parties at the addresses set forth on the signature pages attached hereto (or at such other addresses as shall be specified by notice given in accordance with this Section 5.4).</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">5.5<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Severability</u>.&#160; If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">5.6<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Aggregation of Stock</u>.&#160; All Shares held or acquired by Affiliated entities or Persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">5.7<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Entire Agreement</u>.&#160; This Agreement and the documents referred to herein constitute the entire agreement among the parties and no party shall be liable or bound to any other party in any manner by any warranties, representations or covenants except as specifically set forth herein or therein.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">5.8<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Amendments; Waivers</u>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and the Requisite Holders or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts an Investor (or group of Investors), the consent of at least 50.1% in interest of the Securities of such disproportionately impacted Investor (or group of Investors) shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of the Investor relative to the comparable rights and obligations of the other Investors shall require the prior written consent of such adversely affected Investor. Any amendment effected in accordance with this Section 5.8 shall be binding upon each Investor and holder of Securities and the Company.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_23"></a>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">5.9<font style="width: 23.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Successors and Assigns</u>.&#160; This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.&#160; The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Investor (other than by merger).&#160; The Investor may assign any or all of its rights under this Agreement to any Person to whom the Investor assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of this Agreement and the Warrants that apply to the Investor.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">5.10<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Further Assurances</u>. Each of the Company and the Investors shall use its respective commercially reasonable efforts to take, or cause to be taken, all actions to assist and cooperate with the other parties hereto in doing all necessary items to consummate the transactions hereby contemplated.</p>
    <p style="text-indent: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">5.11<font style="width: 18.5pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Fees</u>.&#160; The Company shall reimburse the Investors a non-accountable amount of US$15,000. for all costs and expenses of outside counsel and disbursements of Bevilacqua PLLC, counsel to one of the Investors, which shall be withheld by such Investor from its purchase price at the Closing.&#160; In addition, the Company shall be responsible for the payment of any placement agent's fees, financial advisory fees, transfer agent fees, DTC (fees or broker's commissions (other than for Persons engaged by any Buyer) relating to or arising out of the transactions contemplated hereby.&#160; The Company shall pay, and hold each Buyer harmless against, any liability, loss or expense (including, without limitation, reasonable attorneys' fees and out-of-pocket expenses) arising in connection with any claim relating to any such payment.&#160; Except as otherwise set forth in the Transaction Documents, each party to this Agreement shall bear its own expenses in connection with the sale of the Securities to the Investors.</p>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;">[Signature page follows]</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_24"></a>
    <p style="text-indent: 18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;"><font style="width: 18pt; text-indent: 0pt; display: inline-block;">&#160;</font>IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.&#160;</p>
    <table style="border-collapse: collapse; font-size: 10pt; width: 100%;" cellspacing="0" cellpadding="0">
        <tr>
            <td style="margin-bottom: 0pt; vertical-align: top;" colspan="2"><b>FLORA GROWTH CORP.</b><br><br><br><br></td>
            <td style="margin-bottom: 0pt; vertical-align: top; width: 2%;">&#160;</td>
            <td style="margin-top: 0pt; vertical-align: top; width: 49%;"><u>Address for Notice:<br></u><br>3230 W. Commercial Boulevard Suite 180<br>Fort Lauderdale, FL 33309</td>
        </tr>
        <tr>
            <td style="margin-bottom: 0pt; vertical-align: top; width: 5%;">By:</td>
            <td style="margin-bottom: 0pt; vertical-align: top; width: 44%; border-bottom: 0.75pt solid #000000;">&#160;</td>
            <td style="margin-bottom: 0pt; vertical-align: top; width: 2%;">&#160;</td>
            <td style="margin-top: 0pt; vertical-align: top; width: 49%;">&#160;</td>
        </tr>
        <tr>
            <td style="margin-bottom: 0pt; width: 5%;">&#160;</td>
            <td style="margin-bottom: 0pt; width: 44%;">Name: Clifford Starke<br>Title: Chief Executive Officer<br><br></td>
            <td style="margin-bottom: 0pt; width: 2%;">&#160;</td>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 49%;">&#160;</td>
        </tr>
        <tr>
            <td style="margin-bottom: 0pt; width: 5%;" colspan="2">With a copy to (which shall not constitute notice):</td>
            <td style="margin-bottom: 0pt; width: 2%;">&#160;</td>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 49%;">&#160;</td>
        </tr>
        <tr>
            <td style="margin-bottom: 0pt; width: 5%;">&#160;</td>
            <td style="margin-bottom: 0pt; width: 44%;">&#160;</td>
            <td style="margin-bottom: 0pt; width: 2%;">&#160;</td>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 49%;">&#160;</td>
        </tr>
        <tr>
            <td style="margin-bottom: 0pt; width: 5%;" colspan="2">Dorsey &amp; Whitney LLP<br>Attention: Richard Raymer, Esq.<br>66 Wellington St. W, Suite 3400<br>Toronto, ON M5K 1E6, Canada<br>Email: raymer.richard@dorsey.com</td>
            <td style="margin-bottom: 0pt; width: 2%;">&#160;</td>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 49%;"><b>&#160;</b></td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; text-align: center; margin-top: 10pt;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</p>
    <p style="margin-top: 0pt; text-align: center; margin-bottom: 10pt;">SIGNATURE PAGE FOR INVESTORS FOLLOWS]</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_25"></a>
    <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Name of Investor:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">Roxy Capital Corporation &#160; &#160; &#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;"><i>Signature of Authorized Signatory of Investor</i>:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Name of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Title of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">Member&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Email Address of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Address for Notice to Investor:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;" colspan="1">Address for Delivery of Securities to Investor (if not same as address for notice):</td>
        </tr>
        <tr>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Subscription Amount:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">US$&#160;&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Number of Shares Purchased:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Number of Prefunded Warrants Purchased:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_26"></a>
    <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Name of Investor:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">RJL Capital 18</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;"><i>Signature of Authorized Signatory of Investor</i>:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Name of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Title of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">Member</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Email Address of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Address for Notice to Investor:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Address for Delivery of Securities to Investor (if not same as address for notice):</td>
        </tr>
        <tr>
            <td style="width: 5%; white-space: nowrap; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Subscription Amount:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">US$&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Number of Shares Purchased:</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Number of Prefunded Warrants Purchased:</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_27"></a>
    <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Name of Investor:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">Daniel Farb</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;"><i>Signature of Authorized Signatory of Investor</i>:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Name of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Title of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">Member</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Email Address of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Address for Notice to Investor:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Address for Delivery of Securities to Investor (if not same as address for notice):</td>
        </tr>
        <tr>
            <td style="width: 5%; white-space: nowrap; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Subscription Amount:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">US$&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Number of Shares Purchased:</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Number of Prefunded Warrants Purchased:</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_28"></a>
    <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Name of Investor:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">Proof Group Capital Partners II LP</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;"><i>Signature of Authorized Signatory of Investor</i>:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Name of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Title of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">Member</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Email Address of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Address for Notice to Investor:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Address for Delivery of Securities to Investor (if not same as address for notice):</td>
        </tr>
        <tr>
            <td style="width: 5%; white-space: nowrap; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Subscription Amount:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">US$&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Number of Shares Purchased:</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Number of Prefunded Warrants Purchased:</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_29"></a>
    <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Name of Investor:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">BCL Sunset,LLC</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;"><i>Signature of Authorized Signatory of Investor</i>:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Name of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Title of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">Member</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Email Address of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Address for Notice to Investor:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Address for Delivery of Securities to Investor (if not same as address for notice):</td>
        </tr>
        <tr>
            <td style="width: 5%; white-space: nowrap; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Subscription Amount:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">US$&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Number of Shares Purchased:</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Number of Prefunded Warrants Purchased:</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_30"></a>
    <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Name of Investor:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">GPO Holding Corp</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;"><i>Signature of Authorized Signatory of Investor</i>:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Name of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Title of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">Member</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Email Address of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Address for Notice to Investor:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Address for Delivery of Securities to Investor (if not same as address for notice):</td>
        </tr>
        <tr>
            <td style="width: 5%; white-space: nowrap; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Subscription Amount:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">US$&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Number of Shares Purchased:</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Number of Prefunded Warrants Purchased:</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_31"></a>
    <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Name of Investor:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">1234561 Ontario Inc.</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;"><i>Signature of Authorized Signatory of Investor</i>:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Name of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Title of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">Member</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Email Address of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Address for Notice to Investor:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Address for Delivery of Securities to Investor (if not same as address for notice):</td>
        </tr>
        <tr>
            <td style="width: 5%; white-space: nowrap; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Subscription Amount:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">US$&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Number of Shares Purchased:</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Number of Prefunded Warrants Purchased:</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_32"></a>
    <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Name of Investor:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">Mathew Lazarus</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;"><i>Signature of Authorized Signatory of Investor</i>:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Name of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Title of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">Member</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Email Address of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Address for Notice to Investor:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Address for Delivery of Securities to Investor (if not same as address for notice):</td>
        </tr>
        <tr>
            <td style="width: 5%; white-space: nowrap; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Subscription Amount:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">US$&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Number of Shares Purchased:</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Number of Prefunded Warrants Purchased:</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_33"></a>
    <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Name of Investor:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">Bevilacqua PLLC</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;"><i>Signature of Authorized Signatory of Investor</i>:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Name of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Title of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">Member</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Email Address of Authorized Signatory:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Address for Notice to Investor:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Address for Delivery of Securities to Investor (if not same as address for notice):</td>
        </tr>
        <tr>
            <td style="width: 5%; white-space: nowrap; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Subscription Amount:&#160;</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">US$&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Number of Shares Purchased:</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 5%; white-space: nowrap;">Number of Prefunded Warrants Purchased:</td>
            <td style="width: 95%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_34"></a>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><u><b>Exhibit A</b></u></p>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><b>Form of Prefunded Warrant</b></p>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;">[<i>See attached</i>.]</p>
    <hr style="page-break-after: always;" width="100%" size="5" color="black" noshade="noshade"><a name="page_35"></a>
    <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;"><b>NEITHER THIS SECURITY NOR THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS SECURITY HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE AND THIS SECURITY WAS ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") AND SIMILAR EXEMPTIONS UNDER APPLICABLE STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN "ACCREDITED INVESTOR" AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</b></p>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><b>PRE-FUNDED COMMON SHARE PURCHASE WARRANT</b></p>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><b>FLORA GROWTH CORP.</b></p>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt;">
                <p style="margin-top: 10pt; margin-bottom: 10pt;">Warrant Shares: _____</p>
            </td>
        </tr>
    </table>
    <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">This PRE-FUNDED COMMON SHARE PURCHASE WARRANT (this "<b>Warrant</b>"), dated May 2, 2025, certifies that, for value received, _____ or its assigns (the "<b>Holder</b>") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time from and after the date hereof (the "<b>Initial Exercise Date</b>") and until this Warrant is exercised in full (the "<b>Termination Date</b>") but not thereafter, to subscribe for and purchase from Flora Growth Corp., an Ontario corporation (the "<b>Company</b>"), up to _____ Common Shares, no par value per share (the "<b>Common Shares</b>") (as subject to adjustment hereunder, the "<b>Warrant Shares</b>"). The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in <u>Section 2(b)</u>.</p>
    <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;"><u><b>Section 1</b></u><b>.</b> <u><b>Definitions</b></u><b>.</b> Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the "<b>Securities Purchase Agreement</b>"), dated May 2, 2025, by and between the Company and the several investors party thereto.</p>
    <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;"><u><b>Section 2</b></u><b>.</b> <u><b>Exercise</b></u><b>.</b></p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">a) <u>Exercise of Warrant</u>. <font style="background-color: #ffffff;">E</font>xercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by email (or email attachment) of the Notice of Exercise in the form annexed hereto (the "<b>Notice of Exercise</b>"). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in <u>Section 2(d)(i)</u> herein) following the date the Holder delivers the Notice of Exercise, the Holder shall deliver to the Company the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier's check drawn on a United States bank unless the cashless exercise procedure specified in <u>Section 2(c)</u> below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver to the Holder any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. <b>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</b></p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_36"></a>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">b) <u>Exercise Price</u>. The aggregate exercise price of this Warrant, except for a nominal exercise price of US$0.0001 per Warrant Share, was pre-funded to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise price of US$0.0001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination Date. The remaining unpaid exercise price per Common Share under this Warrant shall be US$0.0001 (subject to adjustment hereunder, the "<b>Exercise Price</b>").</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">c) <u>Cashless Exercise</u>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a "<u>cashless exercise</u>" in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(A) =&#160; &#160; &#160; &#160; as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to <u>Section 2(a)</u> hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to <u>Section 2(a)</u> hereof on a Trading Day prior to the opening of "regular trading hours" (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Shares on the principal Trading Market as reported by Bloomberg L.P. ("<b>Bloomberg</b>") as of the time of the Holder's execution of the applicable Notice of Exercise if such Notice of Exercise is executed during "regular trading hours" on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of "regular trading hours" on a Trading Day) pursuant to <u>Section 2(a)</u> hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to <u>Section 2(a)</u> hereof after the close of "regular trading hours" on such Trading Day;</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(B) =&#160; &#160; &#160; &#160; the Exercise Price of this Warrant, as adjusted hereunder; and</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(X) =&#160; &#160; &#160; &#160; the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary to this <u>Section 2(c)</u>.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">"<u>Bid Price</u>" means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Shares are then listed or quoted on a Trading Market, the bid price of the Common Shares for the time in question (or the nearest preceding date) on the Trading Market on which the Common Shares are then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Shares for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Shares are not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Shares are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Shares so reported, or (d) in all other cases, the fair market value of a Common Share as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_37"></a>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">"<u>VWAP</u>" means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Shares are then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Share for such date (or the nearest preceding date) on the Trading Market on which the Common Shares are then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Shares for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Shares are not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Shares are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per Common Share so reported, or (d) in all other cases, the fair market value of a s Common Share as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">"<u>Trading Market</u>" means any of the following markets or exchanges on which the Common Shares are listed or quoted for trading on the date in question: the New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market, the OTCQX, or the OTCQB.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">d) <u>Mechanics of Exercise</u>.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">i. <u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder's or its designee's balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system ("<b>DWAC</b>") if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company's share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the "<b>Warrant Share Delivery Date</b>"). <u>provided</u>, <u>however</u>, that if payment of the aggregate Exercise Price is received after 12:00 P.M., New York City time on the Warrant Share Delivery Date, then the Warrant Share Delivery Date shall be extended by one (1) additional Trading Day. Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Shares on the date of the applicable Notice of Exercise), $5 per Trading Day (increasing to $10 per Trading Day on the fifth Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, "<b>Standard Settlement Period</b>" means the standard settlement period, expressed in a number of Trading Days, on the Company's primary Trading Market with respect to the Common Shares as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Securities Purchase Agreement, the Company agrees to use reasonable efforts to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the date following the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_38"></a>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">ii. <u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">iii. <u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to <u>Section 2(d)(i)</u> by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">iv. <u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of <u>Section 2(d)(i)</u> above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder's brokerage firm otherwise purchases, Common Shares to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a "<b>Buy-In</b>"), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder's total purchase price (including brokerage commissions, if any) for the Common Shares so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of Common Shares that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Shares having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise Common Shares with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder's right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company's failure to timely deliver the Common Shares upon exercise of the Warrant as required pursuant to the terms hereof.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">v. <u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">vi. <u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_39"></a>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">vii. <u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">viii. <u>Legend</u>. Unless and until there is an effective registration statement under the Securities Act and under applicable state securities or blue sky laws registering the Warrant Shares, all Warrant Shares issued shall bear the following legend:</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE AND THIS SECURITY WAS ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") AND SIMILAR EXEMPTIONS UNDER APPLICABLE STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN "ACCREDITED INVESTOR" AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">e) <u>Holder's Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to <u>Section 2</u> or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder's Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder's Affiliates (such Persons, "<b>Attribution Parties</b>")), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of Common Shares beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of Common Shares issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of Common Shares which would be issuable upon (i) exercise of the remaining, non-exercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or non-converted portion of any other securities of the Company (including, without limitation, any other Common Share Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this <u>Section 2(e)</u>, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this <u>Section 2(e)</u> applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder's determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company&#160; shall not have an obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this <u>Section 2(e)</u>, in determining the number of outstanding Common Shares, a Holder may rely on the number of outstanding Common Shares as reflected in (A) the Company's most recent periodic or annual report filed with the Securities and Exchange Commission (the "<b>Commission</b>"), as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of Common Shares outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of Common Shares then outstanding. In any case, the number of outstanding Common Shares shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding Common Shares was reported. The "<b>Beneficial Ownership Limitation</b>" shall be 4.99% of the number of Common Shares outstanding immediately after giving effect to the issuance of Common Shares issuable upon exercise of this Warrant. Any change in the Beneficial Ownership Limitation will not be effective until the 61<sup>st</sup> day after such change is agreed to. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this <u>Section 2(e)</u> to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_40"></a>
    <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;"><u>Section 3</u>. <u>Certain Adjustments</u>.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">a) <u>Stock Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on its Common Shares or any other equity or equity equivalent securities payable in Common Shares (which, for avoidance of doubt, shall not include any Common Shares issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding Common Shares into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding Common Shares into a smaller number of shares, or (iv) issues by reclassification of the Common Shares any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Common Shares (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of Common Shares outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this <u>Section 3(a)</u> shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">b) <u>Subsequent Rights Offerings</u>. In addition to (but without duplication of) any adjustments pursuant to <u>Section 3(a)</u> above, if at any time the Company grants, issues or sells any Common Share Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of Common Shares (the "<b>Purchase Rights</b>"), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of Common Shares acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Common Shares are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder's right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such Common Shares as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_41"></a>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">c) <u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of Common Shares, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a "<b>Distribution</b>"), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of&#160; Common Shares acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Shares are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Common Shares as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">d) <u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any material subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Shares are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Shares, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Shares or any compulsory share exchange pursuant to which the Common Shares are effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding Common Shares or becomes the beneficial owner of 50% of the voting power represented by our outstanding Common Shares (not including any Common Shares held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a "<b>Fundamental Transaction</b>"), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in <u>Section 2(e)</u> on the exercise of this Warrant), the number of Common Shares of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the "<b>Alternate Consideration</b>") receivable as a result of such Fundamental Transaction by a holder of the number of Common Shares for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in <u>Section 2(e)</u> on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one Common Share in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Shares are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the "<b>Successor Entity</b>") to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this <u>Section 3(d)</u> pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the Common Shares acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the Common Shares pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the "Company" shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_42"></a>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">e) <u>Calculations</u>. All calculations under this <u>Section 3</u> shall be made by the Company to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this <u>Section 3</u>, the number of Common Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of Common Shares (excluding treasury shares, if any) issued and outstanding.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">f) <u>Notice to Holder</u>.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">i. <u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this <u>Section 3</u>, the Company shall promptly deliver to the Holder by facsimile or email<font style="background-color: #ffffff;">&#160;</font>a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">ii. <u>Notice to Allow Exercise by Holder</u>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Shares, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Shares, (C) the Company shall authorize the granting to all holders of the Common Shares rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Shares, any consolidation or merger to which the Company (or any of its material subsidiaries) is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Shares is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company<font style="background-color: #ffffff;">, </font>at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Shares of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of Common Shares of record shall be entitled to exchange their Common Shares for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the material subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_43"></a>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">g) <u>Voluntary Adjustment By Company</u>. Subject to applicable securities laws and the rules and regulations of the Trading Market, the Company may at any time during the term of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company.</p>
    <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;"><u>Section 4</u>. <u>Transfer of Warrant</u>.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">a) <u>Transferability</u>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the office of the Company designated for such purpose, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an Assignment Form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">b) <u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with <u>Section 4(a)</u>, as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">c) <u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the "<b>Warrant Register</b>"), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p>
    <p style="text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;"><font style="width: 36pt; text-indent: 0pt; display: inline-block;">&#160;</font><u>Section 6</u>. <u>Miscellaneous</u>.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">a) <u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in <u>Section 2(d)(i)</u>, except as expressly set forth in <u>Section 3</u>. Without limiting any rights of a Holder to receive Warrant Shares on a "cashless exercise" pursuant to <u>Section 2(c)</u> or to receive cash payments pursuant to <u>Section 2(d)(i)</u> and <u>Section 2(d)(iv)</u> herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">b) <u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">c) <u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_44"></a>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">d) <u>Authorized Shares</u>.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Shares a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Shares may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and non-assessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">e) <u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof.&#160; The Company and the Holder agree that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against the Company, the Holder or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York, Borough of Manhattan. The Company and the Holder each irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in New York, New York for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of this Warrant), and hereby irrevocably waives, and agrees not to assert in any action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such action or proceeding is improper or is an inconvenient venue for such proceeding.&#160; The Company and the Holder each irrevocably waives personal service of process and consents to process being served in any such action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof.&#160; Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.&#160; If the Company or the Holder shall commence an action or proceeding to enforce any provisions of this Warrant, the prevailing party in such action or proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys' fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_45"></a>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">f) <u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will have restrictions upon resale imposed by state and federal securities laws.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">g) <u>Non-waiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder's rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys' fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">h) <u>Notices</u>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Securities Purchase Agreement.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">i) <u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Shares or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">j) <u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">k) <u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">l) <u>Amendment</u>.&#160; This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">m) <u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p>
    <p style="margin-left: 36pt; text-indent: 36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">n) <u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_46"></a>
    <p style="text-indent: 72pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;"><b>IN WITNESS WHEREOF</b>, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p>
    <table style="width: 100%; font-size: 10pt; border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 50%;">&#160;</td>
            <td colspan="2"><b>FLORA GROWTH CORP.</b></td>
        </tr>
        <tr>
            <td>&#160;</td>
            <td style="width: 5%;">&#160;</td>
            <td>&#160;</td>
        </tr>
        <tr>
            <td>&#160;</td>
            <td>By:</td>
            <td style="border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
        <tr>
            <td>&#160;</td>
            <td>&#160;</td>
            <td>Name: Dany Vaiman</td>
        </tr>
        <tr>
            <td>&#160;</td>
            <td>&#160;</td>
            <td>Title: Chief Financial Officer</td>
        </tr>
    </table>
    <br>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_47"></a>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><b>NOTICE OF EXERCISE</b></p>
    <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">TO: FLORA GROWTH CORP.</p>
    <p style="text-indent: 72pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(1)<font style="display: inline-block; width: 10pt;">&#160;</font>The undersigned hereby elects to purchase __________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p>
    <p style="text-indent: 72pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(2)<font style="display: inline-block; width: 10pt;">&#160;</font>Payment shall take the form of (check applicable box):</p>
    <p style="margin-left: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">&#9744; in lawful money of the United States; or</p>
    <p style="margin-left: 108pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">&#9744; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p>
    <p style="text-indent: 72pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">(3)<font style="display: inline-block; width: 10pt;">&#160;</font>Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p>
    <p style="text-align: justify; margin-left: 108pt; margin-top: 10pt; margin-bottom: 10pt;">___________________________________________________</p>
    <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p>
    <p style="text-align: justify; margin-left: 108pt; margin-top: 10pt; margin-bottom: 10pt;">___________________________________________________</p>
    <p style="text-align: justify; margin-left: 108pt; margin-top: 10pt; margin-bottom: 10pt;">___________________________________________________</p>
    <p style="text-align: justify; margin-left: 108pt; margin-top: 10pt; margin-bottom: 10pt;">___________________________________________________</p>
    <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">[SIGNATURE OF HOLDER]</p>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 10%; white-space: nowrap;">Name of Investing Entity:&#160;</td>
            <td style="width: 90%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 10%; white-space: nowrap;"><i>Signature of Authorized Signatory of Investing Entity</i>:&#160;</td>
            <td style="width: 90%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 10%; white-space: nowrap;">Name of Authorized Signatory:&#160;</td>
            <td style="width: 90%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 10%; white-space: nowrap;">Title of Authorized Signatory:&#160;</td>
            <td style="width: 90%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 3%; white-space: nowrap;">Date:</td>
            <td style="width: 90%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_48"></a>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><b>ASSIGNMENT FORM</b></p>
    <p style="text-indent: 11pt; text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><i>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</i></p>
    <p style="text-indent: 11pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p>
    <table style="width: 50%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; white-space: nowrap;">Name:&#160;</td>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 70.8189%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; white-space: nowrap;">Address:&#160;</td>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 70.8189%;">&#160;</td>
        </tr>
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 1%; white-space: nowrap; border-bottom: 0.75pt solid #000000;">&#160;</td>
            <td style="margin-top: 0pt; margin-bottom: 0pt; width: 70.8189%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 50%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 1%; vertical-align: top; white-space: nowrap;">Phone Number:&#160;</td>
            <td style="width: 70.8189%; vertical-align: top; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 50%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 1%; vertical-align: top; white-space: nowrap;">Email Address:&#160;</td>
            <td style="width: 70.8189%; vertical-align: top; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 50%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 1%; white-space: nowrap;">Dated:&#160;</td>
            <td style="width: 35%; border-bottom: 0.75pt solid #000000;">&#160;</td>
            <td style="width: 1%;">,</td>
            <td style="width: 2.5%; border-bottom: 0.75pt solid #000000;">&#160;</td>
            <td style="width: 1%;">&#160;</td>
            <td style="width: 20%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 50%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 1%; white-space: nowrap;">Holder's Signature:&#160;</td>
            <td style="width: 70.8189%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <table style="width: 50%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 1%; white-space: nowrap;">Holder's Address:&#160;</td>
            <td style="width: 70.8189%; border-bottom: 0.75pt solid #000000;">&#160;</td>
        </tr>
    </table>
    <br>
    <hr width="100%" size="5" color="black" noshade="noshade">
</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>flgc-20250502.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated by Newsfile Corp. (www.newsfilecorp.com) -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.floragrowth.com/20250502" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:flgc="http://www.floragrowth.com/20250502" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="flgc-20250502_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="flgc-20250502_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="flgc-20250502_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="flgc-20250502_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="DocumentAndEntityInformationDocument" roleURI="http://www.floragrowth.com/role/DocumentAndEntityInformationDocument">
        <link:definition>0001000 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <!-- Start custom elements -->
	<xsd:element id="flgc_CommonSharesNoParValueMember" name="CommonSharesNoParValueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />

  <!-- End custom elements -->
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>flgc-20250502_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated by Newsfile Corp. (www.newsfilecorp.com) -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<link:roleRef roleURI="http://www.floragrowth.com/role/DocumentAndEntityInformationDocument" xlink:href="flgc-20250502.xsd#DocumentAndEntityInformationDocument" xlink:type="simple" />
<link:calculationLink xlink:role="http://www.floragrowth.com/role/DocumentAndEntityInformationDocument" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>flgc-20250502_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated by Newsfile Corp. (www.newsfilecorp.com) -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.floragrowth.com/role/DocumentAndEntityInformationDocument" xlink:href="flgc-20250502.xsd#DocumentAndEntityInformationDocument" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.floragrowth.com/role/DocumentAndEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_DocumentInformationTable" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />

	<!-- Address Axis -->

    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable" xlink:to="loc_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="loc_dei_AddressTypeDomain_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="loc_dei_AddressTypeDomain" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_FormerAddressMember" xlink:label="loc_dei_FormerAddressMember" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain" xlink:to="loc_dei_FormerAddressMember" xlink:type="arc" />

	<!-- Exchange Axis -->

    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsExchangeAxis" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable" xlink:to="loc_dei_EntityListingsExchangeAxis" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ExchangeDomain" xlink:label="loc_dei_ExchangeDomain_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="loc_dei_ExchangeDomain_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ExchangeDomain" xlink:label="loc_dei_ExchangeDomain" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="loc_dei_ExchangeDomain" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNYS" xlink:label="loc_exch_XNYS" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain" xlink:to="loc_exch_XNYS" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNAS" xlink:label="loc_exch_XNAS" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain" xlink:to="loc_exch_XNAS" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNGS" xlink:label="loc_exch_XNGS" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain" xlink:to="loc_exch_XNGS" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XTSX" xlink:label="loc_exch_XTSX" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain" xlink:to="loc_exch_XTSX" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XASE" xlink:label="loc_exch_XASE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain" xlink:to="loc_exch_XASE" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNMS" xlink:label="loc_exch_XNMS" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain" xlink:to="loc_exch_XNMS" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNCM" xlink:label="loc_exch_XNCM" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain" xlink:to="loc_exch_XNCM" xlink:type="arc" />

	<!-- Class of Stock Axis -->

    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable" xlink:to="loc_us-gaap_StatementClassOfStockAxis" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="loc_us-gaap_ClassOfStockDomain_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="loc_us-gaap_ClassOfStockDomain" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_us-gaap_CommonStockMember" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_us-gaap_CommonClassAMember" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_us-gaap_CommonClassBMember" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_us-gaap_PreferredStockMember" xlink:type="arc" />
	<link:loc xlink:href="flgc-20250502.xsd#flgc_CommonSharesNoParValueMember" xlink:label="loc_flgc_CommonSharesNoParValueMember" xlink:type="locator" />
	<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_flgc_CommonSharesNoParValueMember" xlink:type="arc" />


	<!-- Document info -->

    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_DocumentType" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentCreationDate" xlink:label="loc_dei_DocumentCreationDate" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_DocumentCreationDate" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_DocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_DocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_AmendmentFlag" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_AmendmentDescription" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_dei_NoTradingSymbolFlag" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_NoTradingSymbolFlag" xlink:type="arc" />

	<!-- Entity info -->

	<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityAddressCountry" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_dei_CountryRegion" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_CountryRegion" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_CityAreaCode" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_LocalPhoneNumber" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityFileNumber" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_dei_EntityInformationFormerLegalOrRegisteredName" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityInformationFormerLegalOrRegisteredName" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityExTransitionPeriod" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_WrittenCommunications" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_SolicitingMaterial" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_PreCommencementTenderOffer" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_CurrentFiscalYearEndDate" xlink:type="arc" />

	<!-- Securities Info -->

    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_Security12bTitle" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" xlink:type="locator" />
    <link:definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_TradingSymbol" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" xlink:type="locator" />
    <link:definitionArc order="34" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_SecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_dei_Security12gTitle" xlink:type="locator" />
    <link:definitionArc order="35" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_Security12gTitle" xlink:type="arc" />

  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>flgc-20250502_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated by Newsfile Corp. (www.newsfilecorp.com) -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	<link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" />
	<link:label id="lab_dei_DocumentInformationTable_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" />

	<!-- Address Axis -->

	<link:label id="lab_dei_EntityAddressesAddressTypeAxis_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ntity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ntity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" />
	<link:label id="loc_dei_AddressTypeDomain_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="loc_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" xlink:type="locator" />
	<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" />
    <link:label id="lab_dei_FormerAddressMember_terseLabel_en-US" xlink:label="lab_dei_FormerAddressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Former Address [Member]</link:label>
    <link:label id="lab_dei_FormerAddressMember_label_en-US" xlink:label="lab_dei_FormerAddressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former Address [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_FormerAddressMember" xlink:label="loc_dei_FormerAddressMember" xlink:type="locator" />
	<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_FormerAddressMember" xlink:to="lab_dei_FormerAddressMember" xlink:type="arc" />

	<!-- Exchange Axis -->

	<link:label id="lab_dei_EntityListingsExchangeAxis_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsExchangeAxis" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" />
	<link:label id="loc_dei_ExchangeDomain_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="loc_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ExchangeDomain" xlink:label="loc_dei_ExchangeDomain" xlink:type="locator" />
	<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" />
    <link:label id="lab_exch_XNYS_terseLabel_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New York Stock Exchange [Member]</link:label>
    <link:label id="lab_exch_XNYS_label_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New York Stock Exchange [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNYS" xlink:label="loc_exch_XNYS" xlink:type="locator" />
	<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNYS" xlink:to="lab_exch_XNYS" xlink:type="arc" />
	<link:label id="lab_exch_XNAS_terseLabel_en-US" xlink:label="lab_exch_XNAS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NASDAQ [Member]</link:label>
    <link:label id="lab_exch_XNAS_label_en-US" xlink:label="lab_exch_XNAS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NASDAQ [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNAS" xlink:label="loc_exch_XNAS" xlink:type="locator" />
	<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNAS" xlink:to="lab_exch_XNAS" xlink:type="arc" />
	<link:label id="lab_exch_XNGS_terseLabel_en-US" xlink:label="lab_exch_XNGS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NASDAQ Global Select Market [Member]</link:label>
    <link:label id="lab_exch_XNGS_label_en-US" xlink:label="lab_exch_XNGS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NASDAQ Global Select Market [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNGS" xlink:label="loc_exch_XNGS" xlink:type="locator" />
	<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNGS" xlink:to="lab_exch_XNGS" xlink:type="arc" />
	<link:label id="lab_exch_XTSX_terseLabel_en-US" xlink:label="lab_exch_XTSX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Toronto Stock Exchange [Member]</link:label>
    <link:label id="lab_exch_XTSX_label_en-US" xlink:label="lab_exch_XTSX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Toronto Stock Exchange [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XTSX" xlink:label="loc_exch_XTSX" xlink:type="locator" />
	<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XTSX" xlink:to="lab_exch_XTSX" xlink:type="arc" />
	<link:label id="lab_exch_XASE_terseLabel_en-US" xlink:label="lab_exch_XASE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NYSE MKT LLC [Member]</link:label>
    <link:label id="lab_exch_XASE_label_en-US" xlink:label="lab_exch_XASE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NYSE MKT LLC [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XASE" xlink:label="loc_exch_XASE" xlink:type="locator" />
	<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XASE" xlink:to="lab_exch_XASE" xlink:type="arc" />
	<link:label id="lab_exch_XNMS_terseLabel_en-US" xlink:label="lab_exch_XNMS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NASDAQ Global Market [Member]</link:label>
    <link:label id="lab_exch_XNMS_label_en-US" xlink:label="lab_exch_XNMS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NASDAQ Global Market [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNMS" xlink:label="loc_exch_XNMS" xlink:type="locator" />
	<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNMS" xlink:to="lab_exch_XNMS" xlink:type="arc" />
	<link:label id="lab_exch_XNCM_terseLabel_en-US" xlink:label="lab_exch_XNCM" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NASDAQ Capital Market [Member]</link:label>
    <link:label id="lab_exch_XNCM_label_en-US" xlink:label="lab_exch_XNCM" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NASDAQ Capital Market [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNCM" xlink:label="loc_exch_XNCM" xlink:type="locator" />
	<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNCM" xlink:to="lab_exch_XNCM" xlink:type="arc" />

	<!-- Class of Stock Axis -->

	<link:label id="lab_us-gaap_StatementClassOfStockAxis_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:type="locator" />
	<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" />
	<link:label id="lab_us-gaap_ClassOfStockDomain_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:type="locator" />
	<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" />
	<link:label id="lab_us-gaap_CommonStockMember_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" xlink:type="locator" />
	<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" />
	<link:label id="lab_us-gaap_CommonClassAMember_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Class A [Member]</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Class A [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember" xlink:type="locator" />
	<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" />
	<link:label id="lab_us-gaap_CommonClassBMember_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Class B [Member]</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Class B [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember" xlink:type="locator" />
	<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" />
	<link:label id="lab_us-gaap_PreferredStockMember_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember" xlink:type="locator" />
	<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" />
	<link:label id="lab_flgc_CommonSharesNoParValueMember_terseLabel_en-US" xlink:label="lab_flgc_CommonSharesNoParValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Shares, no par value [Member]</link:label>
	<link:label id="lab_flgc_CommonSharesNoParValueMember_label_en-US" xlink:label="lab_flgc_CommonSharesNoParValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Shares, no par value [Member]</link:label>
	<link:loc xlink:href="flgc-20250502.xsd#flgc_CommonSharesNoParValueMember" xlink:label="loc_flgc_CommonSharesNoParValueMember" xlink:type="locator" />
	<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flgc_CommonSharesNoParValueMember" xlink:to="lab_flgc_CommonSharesNoParValueMember" xlink:type="arc" />


	<!-- Everything else -->

	<link:label id="lab_dei_DocumentInformationLineItems_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" />
	<link:label id="lab_dei_EntityRegistrantName_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State Country Name</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State Country Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" />
	<link:label id="lab_dei_Security12bTitle_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" />
	<link:label id="lab_dei_Security12gTitle_terseLabel_en-US" xlink:label="lab_dei_Security12gTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(g) Security</link:label>
    <link:label id="lab_dei_Security12gTitle_label_en-US" xlink:label="lab_dei_Security12gTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(g) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_dei_Security12gTitle" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12gTitle" xlink:to="lab_dei_Security12gTitle" xlink:type="arc" />
	<link:label id="lab_dei_SecurityExchangeName_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" />
	<link:label id="lab_dei_TradingSymbol_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" />
    <link:label id="lab_dei_DocumentCreationDate_terseLabel_en-US" xlink:label="lab_dei_DocumentCreationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Creation Date</link:label>
    <link:label id="lab_dei_DocumentCreationDate_label_en-US" xlink:label="lab_dei_DocumentCreationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Creation Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentCreationDate" xlink:label="loc_dei_DocumentCreationDate" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentCreationDate" xlink:to="lab_dei_DocumentCreationDate" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" />
	<link:label id="lab_dei_AmendmentFlag_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" xlink:type="locator" />
	<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" />
	<link:label id="lab_dei_AmendmentDescription_terseLabel_en-US" xlink:label="lab_dei_AmendmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Description</link:label>
    <link:label id="lab_dei_AmendmentDescription_label_en-US" xlink:label="lab_dei_AmendmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Description</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription" xlink:to="lab_dei_AmendmentDescription" xlink:type="arc" />
    <link:label id="lab_dei_NoTradingSymbolFlag_terseLabel_en-US" xlink:label="lab_dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">No Trading Symbol Flag</link:label>
    <link:label id="lab_dei_NoTradingSymbolFlag_label_en-US" xlink:label="lab_dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">No Trading Symbol Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_dei_NoTradingSymbolFlag" xlink:type="locator" />
	<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_NoTradingSymbolFlag" xlink:to="lab_dei_NoTradingSymbolFlag" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" />
    <link:label id="lab_dei_EntityInformationFormerLegalOrRegisteredName_terseLabel_en-US" xlink:label="lab_dei_EntityInformationFormerLegalOrRegisteredName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information, Former Legal or Registered Name</link:label>
    <link:label id="lab_dei_EntityInformationFormerLegalOrRegisteredName_label_en-US" xlink:label="lab_dei_EntityInformationFormerLegalOrRegisteredName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information, Former Legal or Registered Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_dei_EntityInformationFormerLegalOrRegisteredName" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="lab_dei_EntityInformationFormerLegalOrRegisteredName" xlink:type="arc" />
    <link:label id="lab_dei_EntityExTransitionPeriod_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" />
    <link:label id="lab_dei_CountryRegion_terseLabel_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Region code of country</link:label>
    <link:label id="lab_dei_CountryRegion_label_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Region code of country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_dei_CountryRegion" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CountryRegion" xlink:to="lab_dei_CountryRegion" xlink:type="arc" />
	<link:label id="lab_dei_EntityAddressAddressLine2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCountry_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" />
    <link:label id="lab_dei_WrittenCommunications_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" />
    <link:label id="lab_dei_SolicitingMaterial_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" />
    <link:label id="lab_dei_PreCommencementTenderOffer_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" />
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>flgc-20250502_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated by Newsfile Corp. (www.newsfilecorp.com) -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.floragrowth.com/role/DocumentAndEntityInformationDocument" xlink:href="flgc-20250502.xsd#DocumentAndEntityInformationDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.floragrowth.com/role/DocumentAndEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract" xlink:to="loc_dei_DocumentInformationTable" xlink:type="arc" />

	<!-- Address Axis -->

	<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable" xlink:to="loc_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="loc_dei_AddressTypeDomain" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_FormerAddressMember" xlink:label="loc_dei_FormerAddressMember" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain" xlink:to="loc_dei_FormerAddressMember" xlink:type="arc" />

	<!-- Exchange Axis -->

	<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsExchangeAxis" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable" xlink:to="loc_dei_EntityListingsExchangeAxis" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ExchangeDomain" xlink:label="loc_dei_ExchangeDomain" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="loc_dei_ExchangeDomain" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNYS" xlink:label="loc_exch_XNYS" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain" xlink:to="loc_exch_XNYS" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNAS" xlink:label="loc_exch_XNAS" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain" xlink:to="loc_exch_XNAS" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNGS" xlink:label="loc_exch_XNGS" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain" xlink:to="loc_exch_XNGS" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XTSX" xlink:label="loc_exch_XTSX" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain" xlink:to="loc_exch_XTSX" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XASE" xlink:label="loc_exch_XASE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain" xlink:to="loc_exch_XASE" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNMS" xlink:label="loc_exch_XNMS" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain" xlink:to="loc_exch_XNMS" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNCM" xlink:label="loc_exch_XNCM" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain" xlink:to="loc_exch_XNCM" xlink:type="arc" />

	<!-- Class of Stock Axis -->

	<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable" xlink:to="loc_us-gaap_StatementClassOfStockAxis" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="loc_us-gaap_ClassOfStockDomain" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_us-gaap_CommonStockMember" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_us-gaap_CommonClassAMember" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_us-gaap_CommonClassBMember" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_us-gaap_PreferredStockMember" xlink:type="arc" />
	<link:loc xlink:href="flgc-20250502.xsd#flgc_CommonSharesNoParValueMember" xlink:label="loc_flgc_CommonSharesNoParValueMember" xlink:type="locator" />
	<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_flgc_CommonSharesNoParValueMember" xlink:type="arc" />


    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable" xlink:to="loc_dei_DocumentInformationLineItems" xlink:type="arc" />

	<!-- Document info -->

    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_DocumentType" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentCreationDate" xlink:label="loc_dei_DocumentCreationDate" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_DocumentCreationDate" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_DocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_DocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_AmendmentFlag" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_AmendmentDescription" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_dei_NoTradingSymbolFlag" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_NoTradingSymbolFlag" xlink:type="arc" />

	<!-- Entity info -->

	<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityAddressStateOrProvince" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityAddressCountry" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_CityAreaCode" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_dei_CountryRegion" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_CountryRegion" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_LocalPhoneNumber" xlink:type="arc" />
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityFileNumber" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_dei_EntityInformationFormerLegalOrRegisteredName" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityInformationFormerLegalOrRegisteredName" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_EntityExTransitionPeriod" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_WrittenCommunications" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_SolicitingMaterial" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_PreCommencementTenderOffer" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_CurrentFiscalYearEndDate" xlink:type="arc" />

	<!-- Securities info -->

    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_Security12bTitle" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_TradingSymbol" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_SecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_dei_Security12gTitle" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="loc_dei_Security12gTitle" xlink:type="arc" />

 </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>May 02, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentCreationDate', window );">Document Creation Date</a></td>
<td class="text">May  02,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  02,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Flora Growth Corp.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3230 W. Commercial Boulevard, Suite 180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fort Lauderdale<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">US<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State Country Name</a></td>
<td class="text">A6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">842-4989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001790169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FLGC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentCreationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentCreationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,& HEI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( ,& HEI#7J/\[0   "L"   1
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MJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%
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M?^:+X3]>?P%02P$"% ,4    " #!@*):1L=-2)4   #-    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,& HEI#7J/\
M[0   "L"   1              "  <,   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( ,& HEJ97)PC$ 8  )PG   3              "  =\!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ P8"B6L]1W":)!   ?!(
M !@              ("!( @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+
M 0(4 Q0    ( ,& HEJ?H!OPL0(  .(,   -              "  =\,  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ P8"B6I>*NQS     $P(   L
M         ( !NP\  %]R96QS+RYR96QS4$L! A0#%     @ P8"B6APX9>H_
M 0  / (   \              ( !I!   'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( ,& HEHD'INBK0   /@!   :              "  1 2  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,& HEIED'F2&0$
M ,\#   3              "  ?42  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     )  D /@(  #\4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="form8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.floragrowth.com/role/DocumentAndEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>flgc-20250502.xsd</File>
    <File>flgc-20250502_cal.xml</File>
    <File>flgc-20250502_def.xml</File>
    <File>flgc-20250502_lab.xml</File>
    <File>flgc-20250502_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8k.htm">form8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8k.htm": {
   "nsprefix": "flgc",
   "nsuri": "http://www.floragrowth.com/20250502",
   "dts": {
    "schema": {
     "local": [
      "flgc-20250502.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "flgc-20250502_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "flgc-20250502_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "flgc-20250502_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "flgc-20250502_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form8k.htm"
     ]
    }
   },
   "keyStandard": 25,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 55,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 25
   },
   "report": {
    "R1": {
     "role": "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument",
     "longName": "0001000 - Document - Document and Entity Information Document",
     "shortName": "Document and Entity Information Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "CR20250502",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "CR20250502",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Address Type [Domain]",
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Description",
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Class A [Member]",
        "label": "Common Stock Class A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Class B [Member]",
        "label": "Common Stock Class B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "flgc_CommonSharesNoParValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.floragrowth.com/20250502",
     "localname": "CommonSharesNoParValueMember",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Shares, no par value [Member]",
        "label": "Common Shares, no par value [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Region code of country",
        "label": "Region code of country",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Creation Date",
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ntity Addresses, Address Type [Axis]",
        "label": "ntity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State Country Name",
        "label": "Entity Incorporation, State Country Name",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information, Former Legal or Registered Name",
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Listings, Exchange [Axis]",
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange [Domain]",
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Former Address [Member]",
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "No Trading Symbol Flag",
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock [Member]",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(g) Security",
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "exch_XASE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/exch/2023",
     "localname": "XASE",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NYSE MKT LLC [Member]",
        "label": "NYSE MKT LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "exch_XNAS": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/exch/2023",
     "localname": "XNAS",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NASDAQ [Member]",
        "label": "NASDAQ [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "exch_XNCM": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/exch/2023",
     "localname": "XNCM",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NASDAQ Capital Market [Member]",
        "label": "NASDAQ Capital Market [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "exch_XNGS": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/exch/2023",
     "localname": "XNGS",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NASDAQ Global Select Market [Member]",
        "label": "NASDAQ Global Select Market [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "exch_XNMS": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/exch/2023",
     "localname": "XNMS",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NASDAQ Global Market [Member]",
        "label": "NASDAQ Global Market [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "exch_XNYS": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/exch/2023",
     "localname": "XNYS",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New York Stock Exchange [Member]",
        "label": "New York Stock Exchange [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "exch_XTSX": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/exch/2023",
     "localname": "XTSX",
     "presentation": [
      "http://www.floragrowth.com/role/DocumentAndEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Toronto Stock Exchange [Member]",
        "label": "Toronto Stock Exchange [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001062993-25-008357-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062993-25-008357-xbrl.zip
M4$L#!!0    ( ,& HEH(PJEZSZ,  .U9 P /    97AH:6)I=#$P+3$N:'1M
M[+U]<]M&LB_\__D4*-W=:ZD*5B2_)(Z333VT3-LZ*TLZHAQOZM36+9 $):Q)
M@ % R=Q/__3;S/0  XJV+,7K<.O>$XL$!S,]/3W]\NONGR_KV?27__JOGR_3
M9/S+?T7POY_KK)ZFO[R:%F42O2Z+Z_HR.BC*^>[SJ/_Q,AMF=;2_M[L?/8Q>
M9=-T' V749Y>5Q/X8X2/C8K9S]_Q&/_U\W<\[G_]/"S&RZBJE]/T;UN3(J\?
M5MF_T^?[>_/ZIXC^GB2S;+I\_N \FZ55=)Q>1V?%+,D?_+0ET[HLH^ML7%_^
M;6M_;^^O6Q$.\+>MQUO1J("I_FUK.$U&'[:BO*@NDS%\(__8^N7G),J3&7PR
M3R[2_[</'WR7R)AS,Z4Z_5@_3*;91?X\&J5YG98_1;.DO,CRAW4Q?Q[Q1.63
M85'7Q4P^A.&&OPSZ!^_.#L\/^X/H]-W9P9O>H!_U7I_U^V_[Q^<_?S>$5\Y7
MO?)?BZK.)LM/>"?2S(Q$9'D>/?X>GQ]GU7R:+)]'63[-\O3A<%J,/L O_N__
MV?]^[Z>?O\,?_G)^F571RDE'V_5E&FW]O/BE=U&FZ0QH\O-WBU^V=N)HG-2P
M[4D5%9/H;;*,'L71H[U'3^-HF-;7:9I';=:)HR2/3O(Z*;,B0BZ!!^JLR-U;
M#HK9/,F7YAU)/H[29'0)J[A*J[HHHVP,4\@F&;P:?H<_JX!T2;THTP@WMHHN
MTS*MBV@;?Q?##T?3Q3C++Z*LKJ)J,1JE5564%0V=5/CCBJ:%;S^4M]#KZ0E@
M*N#G.KM*I\LX,K,TSU4\S]UHL!C^"QZ+X+WX#/#-K)+?Y^,,EPCO3FM@\;+&
MQ<!30'E+4GITOBBK19+3( -\)ZSOR7:RL_UH!TF,X\+'BQ*&@U7VX&WPZ?Z/
MCQ_'N G V?D8B&(IB=_@4XJ4WP']SA;3-'JZ]WTT+XO98GI!FU@CS1;P^Y+7
M*+L0C=,J*^%E,*.LJA8IS;-*IU/\A/;%4$)ME?NH2J_2,IE.E_1E7M31OXHL
MKY&2:F18]^@RJ=)H C/2K\<!['J% F9FL.)9 5L^6>#P,-JHS(:PDA9I=[N.
M7)8C)SV/?GB$Q^56I_#\33\Z[9W1$7K3/^N_^(T/4-0;1*].CHY.W@^>W\,T
M]G=#XN#1CW9@\ZZ]M04$\-&IV1[<PT$"W--B1F2Q&^F\O_?L"ZQP/[C$Q[M/
M;[=(6A<N\+#",SCZ[$4^>7+K1<*1#R[RT>[WSVZQRE.0N:414 ?3HD*9N WG
M:)Q.X$=P@:?3XGK'%P!P=<)AOTRN@#J+^K(HX;(%&9/ML.0U5,L,U61X*Q\;
MQ_9!A?^:@6 ;7"9P_&,0"B"UR^@JF8)TL;*+OV7)9037O$PG"Q)QUTE9@IST
MA0?_A,]_BG)VAN\VFDK/C7UJQWDOXXB$9&K1>K8S66'69 =Y"WX\A,4OYK"6
M]&-:CK+*/M1^0[0=OD?D^TBO=S<ZMR^*N\;#2>)7_@ 1_!_OQHK@EVE9HH0O
MZ%X$\L".6S)[S+UU/]P][.+NO?U;</<Z%S!MC[X;X@:S)OB%QU5)K8]+;.EN
MKR'\!3$BW8KF+ 0.@C\2_3M?S(9IB=,RV\><'MAOISL$E1ZC\\!+$C?Y>9DQ
MY[X;_&5O]_%>-(>WT:LB> M]^.C''W^DCUOOW)7CT,<KO?6M)QC4"?!?N;>W
MMT^C>VQJ)D@'R&D>]W2!/+J;"T3V]:?H93J%HU>2!KN>7AAF2[ F(K08.B10
MF$W@>$^S=*%8BO>I3CX V<$P2D$BS(H:1<-5EM" Z4?8C/R"7C N1@N< <_1
M\EB%7)> PK_$?UQ?9L 2^%/8[7R4S1-X09F0C@U4_\"LVA#[(Q;[E9&?43$'
M"X&>DY]N)R23SN7/E\G2R7]\+:CNES0%7-"::C7QYQ!MD0KLC(JLAFUXYW4"
M>T2V"W#G+*M1!V;QN(-GB%Y5@P%JA*4][G+\W;&>+>H%:[@D._ ^B&%SZ".T
M5H!<*&%Q?4(W&A;5?=H./ ^H"R.E>4;6$F*.<J:($*!.X^8S0*PZE=OC/UA#
M.<DCNN?;>DI(*1GS06M9(G+_3T&9@5_>J'?O/_U!G?W/ID@6I,@^**P_W((B
M#78>+X"K0-:.%C4[7!15?KJOA897^L/NLR>W6&@")WJ^-#(N Y7EJAC1!9'E
M55TN1GS6K1('4B*O0+4!XB!A#M5#(C6,Q#4/)O1@PXKL&$^&L*^6^[KQ4GB#
MX<'T"MT23DAKH4W'UC G2$)SUZ.C8DH&Z\NS030LB@\/8=1RR;JK;&[CE2@&
MRO0BJ^ B,<9N2EZMUIL4/UR69K-05W@X+-/DP\-D F,\!V%ZG2PKGRG$\;45
M\K,]_50_VZ-N/]L7Y\PP:S[9?7H;S3*;1,E\/LV('4$##"A#ZVX)[M]]'=.K
M("V>WDX>76=EXT3B#9Y$PR3_$"6C4;% *>6N,U]$_:'VQ?[MN&#5W>1?/ZW;
M20N<&^\F6=0TG33H86GT^ ZOJ[W;L4=3_6K=5VL=!Y\$N'&M*;&+^XXNLL>W
MN<BT=O@ _<U#]$S.R9F;S.A\&.78&7UQU! R =4>J$>GSUYHPEGK';T_G-9W
M(IH3G\-B#"F48&[A/V;S:5JSI@W4691 E.@0+MI7>+N^?_@,C_/[AS^2.4!*
MI8D,T/V[PSYUNR7W9)P^OAOC]!W[ID[+8I2F8_9DBGE_KH33J+A*<^M>,JZ-
M2S"(,F/P+ZJ4[S<PNN8RG%%Z*NT;MKP=XF5K\R.161Q6SV5"[P9_>;*W%^_M
M[9FQO'==9S"+88H3&?O^OV*:Y,GG_[[/GH@9C;#_63-89)__X[,,>"VU!N8P
MF6JCOWL,%":@&F*8Q0;4>)CKHOR FNLHF6<U? NOFA>5; J^&DUIV/5)*I^E
M'\$DK]B'"O9U+B&HZZR^7.4+-5-N[_-]A%X>W4G,XRR=P]+@=PEK.;A&654[
M%L6>'GV02O-S_J7V5Y.N(+]W7@0\9#%Z8M)YC6>BX=-(<>(C4#?0WU>-+E,0
M>TCYND[P#[X*O)O7&C8OW0\'YH<F(L@.B>#0?-J'Z)N  <?H54S*F@XN3)Z\
M$?3$[PO8N DS4ND1#?9KG!J?L]Q5L!_*"%,O!G:K$PI"R'I)D%=S]/( "U?"
MBO+#T)IB"433P'@$U%3=-]I?<K-GX N(]$=W%; Z*2^2//LWD3J.7A?%.!K4
M"9,+U_P_M#%P>>$#70(?6";QPO!TG6:Y%21PI5[!.&.Z9,'$,:/#+EW@*ROS
M2I;F2.)I<EVY0$AQE8G$D*A_'!V F!XG-,PEWK' 167Z^R*KLCI5(FQ>7./]
M@-O'@:=ZB6PT@K-$7DB,Y@\7L)MP:>,.Y\4U>07!,$G''8NEY3'+9G)L4)M*
M1K4:BESX[17"!W1V_[4HLVJ<C9CP<F2OD=M8N4^R*3(FC VGIRK4Z]@=Z(T:
M&X??".^ &4CD88K*RV+*X7+R7\+OP&*OBAP4$7R !/6HY@7 *5E,X8(&YL2H
M7 *#@"&:@;Q/QF!_P*CI9((>:(D;3-,+F$^]E(U%JL+X:0[29I0FPVQ*GS0]
MTI&HK&T9'W.L[,;W\CR),XIYRNQ&AQ9$'?S7D#_&:Z["Y9&+V[IYH^U)!JK)
M"%\ GQ=X65]G5;K3].C0]L&/!Z!XP_* Y2B*EGQ(*?*5P%85J&'#(*25WCQS
MY\,VY,'+,RW)38/Q-'BK'0*%EOPV(5<O[EA2(4/ABH8@1N1*,2=F/3)'V_@:
M6"MLLI#<K !=$BCIWYHY]&09?5J&"2J>(,GPHN%5G<(C+>^Y09V U%HM:S7%
M+^GP>00WQX]BC.IS]F7/TH2NU*5,@ISD-J9@L1_C#%5YXT8W?\'B#V'MUS*"
MS+)8U/:@4HC!:CWP8]CP,3^-8H89OLIFV33!@=%M4]765R-30N(>PHOP8BJ+
M*3$C\VW*(DNL!KH591*.AQV'TW/C69:#\!09Z[])X69D&-B-]*(@X4!R:)Q=
M96..,82CN8E/YZ66]A3PIA<U:>\&CO45$-.20)^L+K-Y'$V!3BAIIIEA_I'9
MG[J$RS &/M;W!:Q7WTL78%&4N6%M=,&.B/SS L:"RVF*!C+.H\KXM-&=+;2E
M0QXAVJO6KJ,_U)OY> UOYA=1&^XH3-D3$ ?MST]1G^4^;M!/T:]R(71I"Y=R
M5[G;NN..)H+CT2HXT&5DY3H2T%@3O/GG<CTC=[ST8I,6D=: Q>&1& $_CLE2
ML;8+!UZ53BB\IM?);@1RU, #XL +78;KS-%WOSC@  B4:C&;L2CP'S("H'8#
M5B2 TAGLK0E1#I=N_O#O;8MOC&FU( GYT,H)O,%P6P$M05V^O.*)HI5I1_$
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MG4/7$N,</RY9GZ0IQ^K?)+/Y!#FW0B,D/C%%U[+:N5"1"&V)@W/ I37UVH8
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M@&YVIL8 LMQ;$O",NPG8(%R.X9\IW?\/4X*WPF-1,D;%B3?*N,DE[$$8-:9
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MRY>QM_A]@*BM/H#&,TM5%] 9[!@OHWI7?%Z*W+A3OP^X4_U4PU#ML3E6T4
M-6BG_(45N-REE\2R)ZTY2P+U=BNW;9-"_+.YU:JL$*5TF^@",X]*L,>'.1.+
MZX]AW),&NP;:8:)L2>6YMQ_M_97"RK.B#)4-554UI ^?9+?KXCZC9#I:L(8K
M"C+'+0K;O(]:!KJ6K)AI4Z!VSD4R48WO2%AYLO<TL!4[QI!I5# S.'@ZU\9.
MU8VX.%4NC;8QF,BH2@2!TM;  (SO9@6'ZS%*#NH%]2>,NY\6H:1B?(VV)ELO
M$FRX!)N^A;SO,30NFPL6N84##VZ/=[;W=TBS+:+M*]+,0@TV$YI6^)0869FZ
M2&_2<: TOEU/X1'Q!_[K\4X[Z&'*\ZC:U.@C*"E^;@./ML,C6;$A C8IUS')
M]@3XODO'S1Y/NO4/\0B>4(5/;WNV[*+3'8?3DIQ:!UE3+A)X]]P&_MS0E>M\
MXVZXK\8MMG]O;K$[@@<YG)W6JE0I(+7);O=N[D'D;VYIO6TW:6>FZ$2PN.0:
M?A1V"A#ZA)H+44"P*,M4FAAZ[<=-D:E/:$3T9?H042BD5HT OTP3P/7=D]JC
MAQ.L(H'SVB"5]I\('DEJW7$IM+:B<*.GQJMSAB$EDV)'<)@@:/JQ(&QOU+M^
M>'3K0_9X-U@N]L?;>FY\.N).O'>$;(#$\!"Z_A.(T;';)$14/CRJ#B>EAYJE
MSSL:J\G'.GF6&.+Y?>BUCW>#OOTOT/Y&9VAJ.4:]'K7K6IP$6(C50K%8XS=%
M#:B&F=?,M9#*,ZJ>F4O?S$G)N"@*JD F?3.L6F&@A?AO#\DD.F[FP17E1:J_
M/,9<33%,.Z/8%#LPS3NXL*@M'VRR0[PR>=1EFJ2 M<%\KZYX"M>N/T6NB98C
MV%6D(&=@B2& 1=T*?JG&L+EWKS=VC'6&Z72-^?N3<6 A-S]7QKRB"=%F<G@/
MKB<404-I?.*FBK  V),1H\5-,;'*9ZMV3C$UK -EK3*JXG9"O3O-7@V7VIY?
MMVG+K" 3.5O,%++-L)@%U2B\+X<HR<[@59C+S79:>6 PI1>FH:DD. ^;\Z7W
MZ&+&%*V]2H"]A.W0'# YTQ+\1(JXZD<43P'M<N+0%63_2.4"S/?RXQ=BSU$'
M=?@A:+BL-*C1HW9YMN&RL4&&%2QO2QVDS-ZX-\=EG+.(BQS"D$88J++ N*^8
M;& 5 ?^O6QUA8E);Z"FI_':<[+TQ@1Y<J:!8O.QUF\BA9:*!7-Z+;^/Q;C!"
M\D6*LA\4^00H4C?]@W?,1OY3:W.434M!V3"2J;/XX%"&1?FB33.B3SV\B[*'
M6=84I5^'S)3C-<T;$G0()#BL<FLXC*9=N8\)]2*_K@":+9+:>HC+H'(,2-<'
MD@B/ZTL@M0]"/.F@O</5Q(&1/:+(.U0Q-O+I*#D*2W5=VYOOYK#-R.*'.!#%
M?MC8U'1#_RM/XV+A;\<J]Z?U>8(H01'JZP.8YM!@I')=@EF'1*,'\6B*T;B*
M+Q\4ZJ,=;@7"T%>A*IA<S&!H?%E:"O27V(72&BR*'1USY.%HG84;6;^E,]R3
MR F&IVXO<BQ<I ^J(\7LD;@GU[F!7/F"R),NF9A:+@E*ZQ/6B4H=E;VO'U0-
MTZS5OX'/7%,P/:B<' Q(.W\*(J*013*0++%#!S3+80]34P^<&X*J)&7+:6H*
MB*$7<%5L6J$E\ ]T:Z4676'N,SGQ";!E>FW6Z:44R;E#J<2"%17KO"T2K'_/
M!!R<]F6*"!=EN(:P4263%I$X\=!U*T=/F;ED4\KKB:,+,O0D&\HK8\]. J4Q
MNX6)GZ1*9NEN]&)I-HX^]K5<?T8AG$=[WNWBTJY*'ET,=?*!YNZ5S-/%\FP%
M*O$V4L_"Z31VV8LH G'E_I(K6^='?NCPJ["P<FR[\H1 >FVD2]N\8U8T]%.\
MZH4H^$9HM7_4>?E?C8/QT?TX&!_O!F.WMY>1*H^7TO.L@=MMIML67EE-9\QE
ME6-DE@!#JO\XVW49%G17FG91>F63)IS'PO46C?=<8RE6<U;7N9()7F+O2&#F
M.89X%[G8IDGU0964YFBM38^OK@G4:M+$70*]]I.R5L<>3"FY[#0:$Z4*($]J
M2FHH,W$1@9KQ@7XGA6!=J"N0W><ZZ.H^/JZ]+06\;:!;E8+V<2<!.[["=&:1
M18FMCA<;NR:GW"$#U$OL[IO=Q>1Z796,W*J)ZHZM;AX+7&O*$<;VVH36@$RY
M'X4D&-Z]_6'K?\2TKK0!#!LT=$5Q@4TI_EK:>)SS7#2@<[%4Y<R4@N(CCMA:
MS5QU']V_"BY5:>+<!I9R'I])$)VDN2@1-5PG$PR%8H0A844X!4X /6%$_.P<
M:&;379").$PA>JIB?HGN.N,4P::0EE X8Z^QE$UQ]G(X>:(8!1TRP,P %>6H
MAHX;BRK+E.$SQR>C49,K-!JMR@UG-O=PHMWJGE\S5J;KM"JT])*S91M)B7V4
MNJ;NTOZ5%*R.2_6>SDHP\'7[LV)ITT[D[:D8MZ\Z77<FIL54:2(1;3%<P)*8
M*#9^>++IN>6W:HMH(L!<C#[48L!4M,"T8#[*TF,JE.EV4Z(;F(;;^]BA-L'0
M-/_WL?SW!_GO,_GOC_+??7P0S63\]V,=11<%FWLE1EL2<:;IL ^"S>_A8IG"
MS)) 1<TG3WIHK;8#\ZU.'G?)<L&T\2_BHEJ%OFD &4UG6B>YL?6K LC8JM>Q
MU+#$?[4@,%4# R,"#=O68"7CE"TPAZ&1H3B9UJ)F##Y5("$N"YLFATETXGXV
M?DU!^"875!2&RC17#%G!;J^=>!H/+].%D<$B$RV7NP)9F)$(VW*93BV.,N!A
M,M;%UA"5N,]%E$BMEA:LI'=/'?$>[P9SBV_/LF<IVJ0$#0HGQ/AZGFNLI!(*
M BX#V_&,2V)6T5;I7N0V>DN1TICIS0Z-<'=7,](IJY;19WWVJJI72UJY#\ H
M0Q3 A^66C:JT2A!87P#_C"L"X<--C*9"9C8Z9TG+*-1+$3W'=6DG797'U$Q-
M,8^.2F^$JH.!3&FAN#6.[Q@U$O>&4LVAR6PC1LK\7L!:1>D]:A#K$B*:DAM>
M^G=9N\=;B0+&JA,<9K2 )8:I_<D, 8*ED@@P/[YQ?=9,3:Z *XP"K#23[L(J
M>4CHT3D1F]E"Z4^"B@P> ^N?R[B_55NABCD:,Z4BH>CYB[%P E[8HN%A_YA8
M9M]&%5Q[J )?<1&TBZF:">]Q" O.9#(58YS#R-:"(<?_%IC25PQV9\MS*Y(2
MCKRO'9O:]L4C*0.>&Z\=CT[<9 ;'G!4;E:70+Z=?VDH.WEM#\)1&;@;:&]G4
M-C4DX-O2>;8:S*I'UY7^G/?.<W0;(CM']U?5B&S_\7UYE>ZH W/_XV@Q%3=J
MCXZ(Q9HU@W_.!NJP/KFUHCMTRK&)3:O*&;.'@VE06?X/Y$;Q+% IEF)3YO@;
M5<"9/".!=!4[Q4;?>"G$106BN)F(:GP2:_W/:%VQR4XL=)4 +C\Z3"F^S*:V
MRQT2[4IZ2/J3M;52)-,+Y6)=$-A?@@1<F94+50I"KK8%7OACR;;DTS_KRIM<
MD=!X3]"D.\K)-QD[008]]-%?MB!NH_[27!J%ZJ2,I97@/_S =MSC/:OYVC84
M9QBJHYZD8^Z4G;:"/!U.3<Q#J]AX(V\,Z5<L20F14PS1?-"UPHS.A*SKZ4R!
M+6<[XBIS(2R_S6Q#DQ,V7%2!0+TN=\;*>"H^1:^$I=C!K<DIAT<' TK:H*ZR
M81NF&K75%D=J]#,PH]H6!3"(%QNV2!B!;"CS+$_M22J&?'LWN@](G2WRFUI
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M .<^RV&;.+1$N9E).9M25R2MUG-30-<=V63C4)L"+(F(YD4Z(P<&O,N< U.
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MJY:CV!P;]#'FMA@[&%-8$1+'0+604[BXGX9!0#MGD"K13K]055O4@;@H,56
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M(F?AJ0-2CLA<W7\&&XBYU$F>+V;68L>TPE(:OB<?LQE\)3PQQXK/IDZ 4I5
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MO49.^SKB<^6)M]DA(]M1LEVS+>$B4P_9Y#5UU6DKKM)+[+R+_B@Z<S:O E7
M23'-"FLHRS_\1[0VI J!):![U@Y-&1B,=@4VB\UUOWTNBT([QW$ZDDQMG370
M-4&Z[DDAN'%^L<@\$3O./Y4,X3-A'TJKP).Q#'?S=%7;9-&&REWSC*2M]CCM
M6JA@Y+F(&KE@'1<2S.5K[BWY:.^^4'O[>W?3DO %1O<''Y82Y12\7MO@=6AC
MAS,.1:ZL:>OZZGEP9-UZ3ZK^>$6J)F@G,=S=1OLOF^5;I.5ZR*59*VA-"\K@
M]T#?,FO?\AJADUUE_WJ7TPU$[A?QB]G<2>KX);7=763=W LV<D;>"E-VOY%T
M<D\&SEVU5S^U8LQMD.DZW*&8-92O58J:KYBM5,<:/")I.*:713.V$6Y^L*)9
MB'7B3(N$_%W2V@,7YOIJV#O(M&,8-IF73]8\0#4?]#+&]QIO6Z+:H9FZ2R!^
M@1>,*[&Q>EL;F?G57I%*@UIC#MKG9]O;J?VPJ=H20*HE*\4K_F1C1;9&74.5
M6 %#],I%A-+@=E?GU'2VU5C52Z-%S,]IGQ%J!Z,ZA:3-BNWW) 2"]>*^1%=;
M1%E9#TX _CWP07 6LIU.%@0!D9![" 47BADV\T8\YS/&"O$94-A%\7)9T+$$
M.W"^$@LEK86+@5$:B>BN7+Z>6X/#3J&28*9M8HE=Y6YI"+QM2.Y[*7@"-@@L
M?-L!^BZ2TJ;[N>P)F_2D!S2#29=%J1#;K*NX<U_\=4<M[:D_ZV)4(\H)%GV.
MG@7F*\^53<B52Y3%E;$3NMH_RKXW*E_J]-EFYI#O%+%YZAE5P*/>JJ,R92N?
M>JX*5DM\FVE@ @2?,A T=@71;),&$-4H2:1=R01-/;CJJ]&#]V_6@[] :^.G
M=]+:^"UL7CJ=)GE:+-9L /P%SLO3N^IK_!J-)HJH'F&Z\4 *0D1]]+=QOC<5
M"#/A/N"Q_U8XUY] *''#BPE^CIE8&66^+'Z!Z];C8NNXN:!7FDXD8RZ:4BXD
ME-EPO+ ="+R'*:I:\1[4@O X3J^CWXKR0P/%VLRHEQ(30_(HHR\1D65YG6';
M<0^51QI]'+5%K/%F8M$(F@8"(N:<2315A3QH@/]D6"QIG5(AB>/!6IUVVK1H
ML"4W]Z*^8UQ!@<M<$BK,"%<50%27>J#4G&.8ZU3@[&[#P@R"<M7PK0CQDG_M
M5$NNSY".;9T==O_08,#]4U$%%2RU08&.)'N8TK^D%!H'.\U?"#0WDY(%)%+^
M1R*\OU-3>,HKFF:I-(9F.LELI0\-_%&G=&#LQ\%X!VJQ?&S]PB[N<I..3=TT
MMT[[!2(]/?^;%\-[BKU[S1&!$8N)+B[@*?78J8#@'^B'BST4O3<OU>NI6780
MWK;#8%[&D5#IA39GAAI!+N7I*DT_L&79O6/A';A#4K=YV5_TS286014*AN9)
MO0;7?C+8?YTA<^78%'\SJR>09H:!0 [K=Z'&T-0D5<.FVBRYJYHY%B&DF,I/
M;@H6$B3B7T8W86EKL\BK4*R:@Y2Z6XF1!O*!04J#EI.-8^<N@#&/S%S<>3.0
M"S;4!"G<>"6HZ&F-0QB>9IGFZ [T09!HG=H?E6W9X4Z!N-I;OV)JW<]M<3?X
M-1W#;&PN7@U7Q8C+=.4(;+*'G$Y+A7J%*U.;?AQ-%Q6B 70JC0/;SI%F8#]A
M?<0N+2!V^L !XD.6#EGA.>>P(C"%CV0\8]T-0*#!['/WO3=XPPBTP6P&R,9B
M8Z*4RVHJY8BJ"_^1E,.L=KGO>):7L5'L!:GC5\49+E6N![Z%-2=R1DSYP-FJ
MNFIT0I!3/1 ZO8B:0>5I&Y'97$'+-/TP,D--H@%>"XF^R]3BM5'P*.R'^7'#
MI703&UPGE*!'0H8N!Y$Z^"9@/X'[@5A>V-HTNAQ8X2U 9V31-19+'@G7[UA[
M+O8B$=DT1Q :Q6(1%=-^3>1#M(-SL[D-IIP?^[,SG ,L+Y,TP,7,PP?XUYVZ
MW52ZFJ#\1I+@AAZ&*C:^-HSBB1,+>4HU,9XEV=2YFVQY1XL8A3N@I.*1UDL@
M?@7T)R9D8\\95U_7I%ZUM26;-=1.KG-%Q+HH]I_<T[7?.W@3G?;.SG^+WO3/
M^N<G])\7OT7O>X>_]@<Q=H7'GN*OWAT=]0?G4?\?Y]A0_K1_]O;P_)S[B*M.
M[4>]]]C1_K?H[/#UF_/H\)PZJ[_I_=JG]O+1^1EV/(??_/>[L]^H@WE_<(K-
MXT]>T<^XK7P<'1SU#M^ZSN6G9R<'_?[+P^/7T<O#,WC^Z#=N1V__ZIT=#O#K
MDW<X5BS=T+EE?;.5._5^[[T^ZU-;^MVH30-$0ASTS\X/7V$3=6K*?GP"<SV%
MZ<)/>N= &S-EF2'_O#=P3_5?QD N_&/ TZ4GWQ\.^C$/2?W7]<_?G[P[>@EO
M.H]QVDCV_J]([76)$T>#?O_O2.G^\:N3LX,^;]W)6?_U"1*']O1,X JP-T2D
MP7GO^"5VG'])TP=B#0Y?4A=[_/'A6]I;?/$ YT%S5N/P0&][?P<ZJ>^B7T^.
MW@&AS@YQ;V!HZOW:._C[\<G[H_[+UX:J\%O\%M_D"($T-\R(G/.BWS_&O7YW
M@)/"Q9WW<6.)-?56 F,!][T]03Z@T>#KX]?(Q##^VW?G[X#W>'Z\7MEBLSRB
M.8PW$&8!W?:K<48]NI^@[-.[:L!RP$H&2N]&!3'OZI8@EX0YV**3+JLFXVRD
M1I)2YK:2K!7H$FRBP%8&Z\0. 9@N*=4DQ"HH+C@9S8)WI2PN 5ZW]W>L)D'8
M;6XKRD&:-N"8;@A[WWC-!N$V2Q_2)68C1H1'W]J=CR=;$4/&,!4GH11>*;3A
M!I/ID8$-/R/S@=.D,D%/6^U&J[A+ SV$)Z@A#15[1R\#HR@;;\%>V$+V'87(
MQ96S">E2O E7+ /((ORKEOT:BOHFDG9/;L@[:B]SSH7AJ<S]8LAEXIOE\&KW
M3&6>D:S5%F@/+5+Z:L+(:=:N4/O(1?$SM1+8)X@<"G:= ]<C0UJE7-I>,\3H
MWA''3^^J2<HQJ8<>G7OL;L"/(U>Y#,&WBUP@_A6U F8K QVK-B;;5/U4<H67
MD282Q&J&L"$TXG,J,T]Q,,:W)]-6()A/'^^95#0!J\NF#5:BXHI0P-![,J(Z
MGIB,/]IQ:=QCE[T-ICEU8$S5 $I'1@;B1F&B,&.!!CB/N4W[MA4L8BQE5^,I
MI<)"Z(K /!HX]4;LC6V/U3%7+S/!8,:T2\KUJ+C(J0XS.^?14D ;(Z.8/OE"
MR"C*8>=I1$,EJ1]ORNEBU1_=_$/FJ_>ZL;-VCRJ%?%7V@+'OQ<TAYD'Z&08"
MBDT#S):*A':P1$^$73\LZ\6>8?Z[V7_VY'YBF4_OJG_+@/H0<LZ%/J2'$^(G
M<VVO]#*BF*-*R7QF/(]9&_(T3:YCF^K"@RI3[J/ KB7'->@9&"93C>8,A'^L
M.$W'^K9S+Z0;KBK<^SSIH><?8 %R)Z$#]IZV_HY*Q/8DZ5].[@!;&S3EM$3P
M31WL9.0"TC;+@V-<!L-F>KBX$O.FML#8J6P!G(-!Y]G&YYS?9:M(DC.574*A
M@N'WM!5W5*JP3T%"MYH5.K8ME& [7%BX!2:^<4ZC4H9)T>7A'7HLF14F]<5(
M6TI=,($,LW=2MQT]A*"WCWTW_=S4"^<RTWF>EJ99B:Y!WBA0[G?OD&1+E,8Z
MQ.%$O4OH%.S(/6WT'54\[)F<V,I$M2TZ44FGMH@5RXH\AW#CSXJQJ"4NKU;J
MEN,+\$B:+%:X]\U=[4P@NCK3<0B^;K-VXU9#2N&\,XQR@%J11F^XW5-$V>&-
MD7BNI1UE[M4R!U-FYD5:M,^55ZGH0;UDT)G9+.W#6=YZSDR9D752\RQH?VQB
M)1>Q)@5]C#N ?V6PQA&YFU4++?C_%V6QF'N='G8,;IWZ"-#$ZVB:)K"JIWN[
M^W]%2KCZ$2W@G8G@!V;$<TC'-\Y I_RJH!UQT;7%2G#,@%-#0SU_+'UC%Q?E
M4@VV9V^ $YLJMD&$2HD<2IY+3.-W2I98,$ZJM#SA-MLVA33S##QEPP<W3M;T
M0<EM\HG@/).E3DBUOFRCYUL F[UC7'2A(=]PB[*R!7NSK,M%[*D/#.TN=3K4
M>?"R-N+>-@O$-LN]Q: )F3+5JM!((]'"I0=;8,G,@"A6C]#H/&VA]-Q2E$$5
M@9X:#G#>F+5B:::-(XGMW7&SJOW,\9YQG3"@49>IB$P9"VDFKP!U?LN@K\8W
M^/B^?(-WE%,\6(PPT&)Z,/8(![[*2QC>12ZC)G7C2,M/\W22U=HGIK8Q(^2T
M?K$KH<-0]"I4L1SO4:[-A(]TX+M=U1I]-IQ(T"6,.@^"=Q*W5;U$N ]G:7F1
MECMZ@O91G*',SE0[G]K^5"L48"/5I24B@2>D3) [&TP8TJ8$P"]%0%6+;/^&
M91RH/)RF)C;H%[7 O43]L-U;KC:YB081K%YD%(.5IJ7?$,! ;B@?K)%L<U\8
MR3M*>WHEP6,X/XL296#53L)O:F)-"8TE0HA-G#=EC4)["%XG)Y)4:Z3]Q ^Q
M,*BJ1LO@F:RJ!4I5P(E#G[9K<VW- HW/R,%4,?TI5=95G<XJ::6 L>1$3!4O
MD542*'0^ZWWM\AVE)[U*NUNPF%O6E'!I9))1CV2\(A<Y0XRD. GPQKO!7_:?
MQGM[>[L<[B:G6[-7*-6L6=3H@K;=SR@1):OH?;;%THOT"BQOL/23Z/3HZ""V
M3W.INE9^>=P,W]C.6>T2=>C500ZU^94@/T=I(TW.^J <0"R4=-'1T4QU<B M
M#Y8BL@2K2SVHJ)Q2;/*EDBEJ*UF%'1[X"]N-@IZ7#U^>'T3;$^D%/2R+#RGF
ML>KZMEK$3Y0?A+/FQ\8R?K%88FE,W=6&"@DU$#&K,KJ[&]W8 G:Q58-8.Z*W
MNL)>8H7%DM$A7I:82K*HPBNJ,E6X?<8-Y:K@\8?%Y.$<C@+8\^WB51WH00:_
M: JY2CZ\MQ:Z8KT'#@37*'/7T18TUBC/=J*7*J9LVD+J0CW!XC>Z3KZ79^4=
MED[YY>N6:XNJ_QWXH3LNZ5[]\VO1;I^LH=W>7F"'A?5MJC83V.2X/QA$[Q',
M@*"4 /B0$)=T;8ZMM6)V_M2(.$]%0\-Y,5VZ&#EK07X1/=4EDV,<!1<T\'N6
M< T'U*%')!<H;;[54Y[O"B'-D$"Y#V$/I\F\2I]'YE\_1;CLA[C+AM*&C+#]
MP R8CU)A Y3\XF];>_SW'*4S_\TOXQ>6[@_^8&Q>W]@\>LT5QKU&R=3L/>SU
M3\1E\+;\;UN(G!C^\NKHY*P7O3X[>7_^)CHX.3N%8S2$+TK__W]7CV_];K/N
M1W]5/''SN,2B-P[ZY$<<%?V  GK#FX)#I,]Y!0M:R>-'C_>B][N4Q\?:6_2B
M6$S3*TP3&2S0][;_; ^??(4UCXZ2!6SK.,$(Y*NCZ/'CQWL_^I.&O\HONT=F
M24]Q12^6S[\H\9\\^>M/D3"K_='N#Z!\879;-H[^SQ[][Y.VZ&O8^M"HM]L;
MO0V?20M%]*U?CD%X/P=-+$,#@9#,Y8<4.8W@$_#-)>:1]#^:PM(G7.7SL\_@
M;6F^:D%W3W)/4+WG,/NHF)-.L=WL,*NB,AQEWOGT4_.?3:XOPJ&W&^,_E'(>
MH[T$13)=1O\WF8%\>7^9U:!X1T='IW@ >^B(0M7T>70&[(<7QAEJS64<]:O?
M=_&1[[^/WJ=4Y+&F.JZ[T?M8;I7'3_;H6CDO2M 'BC@Z.8[>/OU[M-__/HX.
MDCP9)_AU'S$JSZ.2!MXM^3W_WYBFM0M6T=>W.:!$F'&'OW3M$?P+M:6FMAH:
M?"V='=3SL_[;WB&CF5]%I[W7?42^]H\1H=H[.OHM.NJ_.H]>'/6._QXP#%K+
M7/'6AD8\.'Q]W#M_=];GE[XB+/6O_<'YR=D _CHZ.GD_^&J,A*<W&PF/O[^U
MD="ETW/Q20J(?HT*?8<JK]7SZ!/T^BUYV&KQM];JG91"1U"=/L01X75Y<5TF
M<U$I= #S^1HG7 ;]\>G:BN!9\7$)(FJ>8>+2@>J]*<X"[S_K28!A^1].^9^S
M7YQ_ ':@Y_AP('RXU#OS\W?9+W>S.W\JLAN&#Y%[0]Y;DY<LD?NE[UOJ6_"G
MHC+I>)%Q5&RX^:[HW'8%H5IQMW?EGXG SG+:]XG]4J7S^!Y[%[?/)F2Y<_>'
MRN:J3FR7HJ8)O[[!M]FUE<<BT/?J;L["N\%?>-P_%7F/;:TX@7@;ZV:\D3A?
MD+B!PGI?$:'_6*O_^XW5O['Z;\ON9_]]9(W^_6=_$OFR,>LW9OVW1]X_S*S_
MD]!W8]!O#/IOCL!?AQ'?-=?-[GT-AOV?A+ K3/J-M+ES8_YK(/$?:\__L+'G
M-_;\;?G^99)GZ31ZE93#/XE\V1CS&V/^VR/OQIC?&//? ITWQOS&F-\8\QMC
M?F/,?V-DW1CS*XWY9QMC?F/,WY;O3ZEITVLJ8&:"]*=)6>=8=^;P,#HZ_9.(
MG8V-O['QOSWR;FS\C8W_+=!Y8^-O;/R-C;^Q\3<V_C=&UHV-O]+&_W%CXV]L
M_-OR_8N#HVB ]2'K^.CHX$\B8C;V_,:>__;(N['G-_;\MT#GC3V_L><W]OS&
MGM_8\]\863?V_"I[_O'>QI[?V/.WY?O7IR?4UPU+[V,5O3^)D-E8]!N+_MLC
M[\:BWUCTWP*=-Q;]QJ+?6/0;BWYCT7]C9-U8]"LM^OV-1;^QZ&_+]_N/'C]Y
M^OU^=)+729GA+3[:_9,(FHU5O['JOSWR;JSZC57_+=!Y8]5OK/J-5;^QZC=6
M_3=&UHU5O]*J?[2QZC=6_6WY_FT"A+R.CI)_)^6B^I.(F(T]O['GOSWR;NSY
MC3W_+=!Y8\]O[/F-/;^QYS?V_#=&UHT]O]*>?[RQYS?V_&WY_D5ZE0&__;Y(
MHM--(OW&H-\8]/^YY-T8]!N#_EN@\\:@WQCT&X-^8]!O#/IOC*P;@WZE0?^D
MVZ#WW[>V\?[SXI>?A[_T/UYFPZR.>C]_-X0WP&?6./XR;QG^\JHH9\$=YE=^
MT=?]+UIO*=Q$=9V,+M,Q&F>[_W0O66,3O]"&/;UQPS[9W0*T/.X?GK_IGT7G
M;PX'T:!_\.[L\/RWZ/@$/^F;#P[[@^AP,'C7>W'4C]Z=GAS3E_U_],\.#@?]
MZ.15X^=O>K_VHQ?]_G%TUG]].#COG_5?HF/G37/0WO%+&.;@3>_X=3\Z.'G[
M%MYR",.W7Z^_? 6_^RT:G/?.^S2"__+W/9XLO/(0)W!TV#L^D&GWCG'6;T_/
M<9Q79R=OZ34\R;,>?7K6_Y]WAV?]M_WC\T'T[OAEOS65WL$YSF'_Q\>/XPA>
MUH-G7\+;MO&Y+?_!K1V:X>#P[>%1[\R]W S=.ST].CP@NO)ZU,^/>N\',?X<
M_L_!P<G9R\/CUT>_Q=';'F[0.1 8IO&*: OT&IP<$2W[I^?1Z;LSV*SC\^C\
MA)8,3QV<'_[:6"F]$->Y8IEGS;%ZO_9@)3A?GY Q/@OT[D4P_/$ ?HS?X#0'
M[U[\-[P>?A_?0&WBH]8<D'XX,)& MI(XZ2;*[3;8@AEE!4MWLS,2'(A]>M1_
M^9JYZN#D^+C/2^3)1"].CGO1J\.7?7CZ[+7,]QV03;Y7!^'%V<G?^V</7_9[
M1T!U(-L)G<"CDYX=[=7A,:STL'<$+QN<'YZ_HU>=O^F=PZ1Q&[9@>!CK\)SF
M\VM_<'YRMH7,^+(/OQ76?P=+>[JWOYWLK-QA]7KZ$J<(Q^O=P1OU\.X=R%80
M/Z=G_8>OWM'QP1..7/FF=]9'K@.I )OQOG<&_'1^-V]_=71RUHM>GYV\!ZH#
M>YTV5OF5*D%ZA:$%\OJ\7_MD6Y=$<JV*AOH\^G_X/TL>I>BLH?;<6<S@'&,
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M D?\"3!F%08"Y!<8$("7>%*@KPU\*J]:-W,&+=<VVXM+O!%?!/<%6"$@V7)
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M$ &1WERCZ<0:9^C? 1-$L;GJ"U.U%3X.?P,7J@N (HB>=NBFPU'=@U%E7.-
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MG6Z,6O=]WVZ9+[ $_,V&>L)@BHW#]#ZK+0!W]Z/2S1L<*4C#]+LQOKB4!8:
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MVB'#HR###?"JKM.BF#6$4 GNC[OL+1A#3K'7%/NB(]#-EN! #[W[=!/G0L$
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M=PVO'T+&KZ3]73X@\,5*BDDP6:8-Z[EKJSRT[-AM&N:#&MR"2[?1R@,KIS[
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MES ?W]:\@A]@"$D0/TL>Q'$'?@RF1B3YP)_EAB,:*CI6QENSA[8UUV!\9?1
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M8O":^KRUYRW<HP;A>.7ZH)CS-]Y_9'XI+;?K:]R"N@R6XUA"/.3KE^N#]\I
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MI+1)+QZ(A"A,2$ #4+'\[POP0Q8E B0A0D8OMD0N@'V?)9=8$M3[#ZLH='Y
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MI8NO Y-1".I-P>Z/+[J\*F@8C_6NH'!*A%?7MP5-S?#7!<YR'=\7@)7V\\9
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MV7/[V:*R1:"M^ 3(LX;(X'VL(*W>$6?B)Z&P^DC\YSI(J?CD_U!+ P04
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M'3?@@);I;$=" )?K3>_51+@UR>S:S'^LF];4$(?Q[-[0D*;M1UXH\DCKQM0
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MD36N$"22,B4\0KVU:9M"WN0O<1QZ1XX@2/9>8OE[QR>99OM%\! 6BT$P\F*
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MZ;,::3 JS-:.YXH9SU[:'M644QG[+O5HY434;C"E8]%"T;-.P%W$3T5JQ(/
M916E3^P-^)?&B.(I)''_S9C'!'4W"$9[SZ4OOJ(R[3@-AYD#7\86A)P )$(U
M3AG;V;C'HFVN76H6]VSS1?+.AW1.O(]+XD-N:+.!M@]4UGCF";Q"HRYX5TS@
MX_$";/^1>6H[[0 )L[J-$ZJ1:\=120TX(8CU86Y\B?.J'>^JL=*&,4@0V<+;
M7A3*/'W+6".=47QO;H.Z7$XGW%7=DZ?\B<?Y!WMQ?:*"50VZT+GF,Y BD-P
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M2B-?Z7G4SR&] G3K.VOU 7_-L_]_4$L! A0#%     @ P8"B6@C"J7K/HP
M[5D#  \              ( !     &5X:&EB:70Q,"TQ+FAT;5!+ 0(4 Q0
M   ( ,& HEHW#-/"U@,  'D2   1              "  ?RC  !F;&=C+3(P
M,C4P-3 R+GAS9%!+ 0(4 Q0    ( ,& HEJ2H!KG2 $  , "   5
M      "  0&H  !F;&=C+3(P,C4P-3 R7V-A;"YX;6Q02P$"% ,4    " #!
M@*):1'*\UZX'  # 6   %0              @ %\J0  9FQG8RTR,#(U,#4P
M,E]D968N>&UL4$L! A0#%     @ P8"B6H6!]!R)#@  G;D  !4
M     ( !7;$  &9L9V,M,C R-3 U,#)?;&%B+GAM;%!+ 0(4 Q0    ( ,&
MHEH%F]U&F0<  %5C   5              "  1G   !F;&=C+3(P,C4P-3 R
M7W!R92YX;6Q02P$"% ,4    " #!@*):H"P&ZGD1   ?5   "@
I    @ 'EQP  9F]R;3AK+FAT;5!+!08     !P ' , !  "&V0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>form8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="flgc-20250502.xsd" xlink:type="simple"/>
    <context id="CR20250502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790169</identifier>
        </entity>
        <period>
            <startDate>2025-05-02</startDate>
            <endDate>2025-05-02</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="CR20250502" id="ixv-164">false</dei:AmendmentFlag>
    <dei:DocumentPeriodEndDate contextRef="CR20250502" id="ixv-165">2025-05-02</dei:DocumentPeriodEndDate>
    <dei:EntityCentralIndexKey contextRef="CR20250502" id="ixv-166">0001790169</dei:EntityCentralIndexKey>
    <dei:EntityTaxIdentificationNumber contextRef="CR20250502" id="EntityTaxIdentificationNumber">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:EntityRegistrantName contextRef="CR20250502" id="EntityRegistrantName">Flora Growth Corp.</dei:EntityRegistrantName>
    <dei:DocumentType contextRef="CR20250502" id="ixv-178">8-K</dei:DocumentType>
    <dei:DocumentCreationDate contextRef="CR20250502" id="ixv-179">2025-05-02</dei:DocumentCreationDate>
    <dei:EntityIncorporationStateCountryCode contextRef="CR20250502" id="ixv-180">A6</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="CR20250502" id="ixv-181">001-40397</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1 contextRef="CR20250502" id="ixv-182">3230 W. Commercial Boulevard, Suite 180</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="CR20250502" id="ixv-183">Fort Lauderdale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="CR20250502" id="ixv-184">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="CR20250502" id="ixv-185">US</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="CR20250502" id="ixv-186">33309</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="CR20250502" id="ixv-187">954</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="CR20250502" id="ixv-188">842-4989</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="CR20250502" id="ixv-189">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="CR20250502" id="ixv-190">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="CR20250502" id="ixv-191">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="CR20250502" id="ixv-192">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="CR20250502" id="ixv-193">Common Shares, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="CR20250502" id="ixv-194">FLGC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="CR20250502" id="ixv-195">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="CR20250502" id="ixv-196">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="CR20250502" id="ixv-197">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
